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Abstract 
Cisplatin is a potent chemotherapeutic agent that is commonly used to treat a wide variety 
of tumours. Although highly effective, its administration is complicated by its ototoxic 
effect, a well known side effect that occurs in a significant number of patients. The 
hearing loss observed is typically irreversible, progressive, bilateral, high-frequency 
sensorineural hearing loss associated with tinnitus. At present there is no approved 
method for protecting or remedying against deterioration of hearing status, therefore, the 
detection and appropriate management of cisplatin-induced ototoxicity is reliant on 
effective audiological monitoring. The present study aimed to investigate the prevalence 
of ototoxicity in head and neck oncology patients who received cisplatin in combination 
with cranial irradiation. In addition, the study also aimed to examine the current state of 
audiological monitoring for this population at Christchurch Hospital. 
Post-treatment diagnostic audiological assessments were performed for 23 participants. 
The post-treatment assessment battery included case history, standard pure-tone 
audiometry (0.25 – 8 kHz), extended high-frequency audiometry (9 – 16 kHz), speech 
audiometry, tympanometry, acoustic reflexes and distortion product otoacoustic 
emissions. Prior to the assessments, a search of the Christchurch Audiology and Ear, Nose 
and Throat (ENT) Department oncology audiogram files was undertaken to match any 
previous audiograms to participating individuals. 
The results showed that pre-treatment assessment had been performed for 16 of the 23 
participants. Of those 16, 15 participants experienced a significant cochleotoxic change in 
their hearing thresholds according to the ASHA criteria. One participant only received 
one dose of cisplatin due to deteriorating hearing, while one other participant elected to 
stop cisplatin treatment after the first dose due to a significant increase in tinnitus 
severity. 
Ototoxicity resulting from cisplatin chemotherapy constitutes a significant clinical 
problem that may have serious vocational, educational, and social consequences. Findings 
from this study highlight the importance of effective audiological monitoring for the 
timely detection and appropriate management of cisplatin-induced ototoxicity. 
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1 Introduction 
Cancer represents a spectrum of disorders resulting from the deregulation of cell growth 
and maturation that occurs normally in organ development during embryogenesis, 
growth, and tissue repair and remodelling after injury (Rybak, Huang, & Campbell, 
2007). Cancers of the head and neck are mostly squamous cell carcinomas (SCC) that 
develop after exposure to carcinogens such as tobacco and alcohol (Argiris, Karamouzis, 
Raben, & Ferris, 2008), and are the sixth most common type of cancer worldwide 
(Parkin, Bray, Ferlay, & Pisani, 2005). Treatment for these epithelial malignancies 
typically involves surgical removal of the tumour and radiotherapy. The incorporation of 
chemotherapy into curative therapy, however, has improved clinical outcomes. The 
platinum compound cisplatin is considered the standard agent in use for the treatment of 
head and neck cancers (Argiris, et al., 2008). Advancements in medical knowledge have 
resulted in notable improvements in relative five-year survival rates not only for head and 
neck cancers, but for many cancer sites and for all cancers combined (Jemal et al., 2008). 
This has serious implications for quality of life post-cancer treatment. A well-recognised 
side effect of cisplatin chemotherapy is ototoxicity, resulting in bilateral high frequency 
sensorineural hearing loss (SNHL) that is typically permanent and associated with 
tinnitus (Daldal, Odabasi, & Serbetcioglu, 2007). Hearing loss can have significant social, 
emotional, educational and vocational implications. There is currently no approved 
method of preventing nor reducing cisplatin-induced ototoxicity. 
Originally, the purpose of this thesis was to cover a Phase III clinical trial at Christchurch 
Hospital, which proposed the trial of intratympanic dexamethasone administration to 
investigate potential protective effects against ototoxicity while preserving cisplatin‘s 
chemotherapeutic actions. Due to significant administrative delays, however, the focus of 
the current study shifted to the prevalence of cisplatin-induced ototoxicity in a subset of 
cancer patients. 
The present study aims to ascertain the current hearing status of individuals who have 
received combined chemotherapy and irradiation therapy for the treatment of head and 
neck cancer. Behavioural and objective measures of auditory function were used in the 
test battery. Data collected from post-treatment assessments were compared to baseline 
data obtained prior to commencing treatment. In addition, this study aims to examine the 
current state of audiological monitoring for this population at Christchurch Hospital. The 
remaining sections of this chapter will provide background to the biochemical basis of 
hearing and the concept of ototoxicity. 
  
2 
1.1 Physiological and biochemical basis of hearing 
The auditory system consists of specialised cells and structures that function both 
independently and in combination with one another to result in normal hearing. 
Disruption to anatomical or physiological components within the auditory pathway may 
result in a loss of hearing sensitivity. This section aims to provide a broad overview of the 
physiological and biochemical basis of peripheral hearing in order to interpret the effect 
of toxicity on the auditory system. 
1.1.1 The peripheral auditory system 
The peripheral auditory system is divided anatomically into three sections: the outer ear, 
consisting of the pinna and external auditory canal (EAC); the middle ear, which is 
bordered by the tympanic membrane (TM) and contains the ossicular chain; and the 
inner ear, which consists of the cochlea, utricle, saccule, and semicircular canals (Figure 
1.1). 
 
Figure 1.1: The peripheral auditory system (adapted from Brödel, 1946) 
The peripheral auditory system is responsible for performing two tasks: converting 
mechanical energy into bioelectrical signals, and coding the frequency, intensity and 
timing information content of these signals (Fuchs, 2010). This is achieved by combining 
multiple elements within the auditory peripheral system. Firstly, airborne vibrations are 
collected by the pinna and directed into the EAC. Sound waves vibrate the tympanic 
membrane and ossicles—the malleus, incus and stapes—transforming acoustic energy to 
mechanical energy. The middle ear functions as an impedance-matching transformer, 
allowing energy to change from one medium (air) to another (fluid) with minimal loss. 
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The cochlea consists of a membranous labyrinth within a bony shell (the osseous 
labyrinth) that is coiled into approximately 2 ½ turns (Yost, 2007). Within the cochlea are 
three distinct ducts: scala vestibuli, which is superior; scala media (also referred to as the 
cochlear duct) which is the central duct; and scala tympani, the inferior duct. Scala 
vestibuli and scala media are separated by Reissner‘s membrane, while the basilar 
membrane (BM) forms the boundary between scala media and scala tympani1. Movement 
of the stapes footplate against the oval window membrane elicits longitudinal waves 
within the cochlear fluids. This stimulates displacement of the BM, which is narrow and 
stiff near the basal end and becomes progressively wider and more flexible toward the 
apex. The stiffness and mass gradients of the BM cause it to vibrate in frequency-specific 
patterns, with maximal vibration for higher frequency tones occurring at the basal end of 
the cochlea, and maximal vibration for lower frequency tones occurring nearer the apex of 
the cochlea. Consequently, frequency is arranged tonotopically along the BM. 
The organ of Corti is situated on top of the BM in scala media and contains a single row of 
inner hair cells (IHCs) and multiple rows of outer hair cells (OHCs). The OHCs are 
positioned closer to the stria vascularis, while the IHCs reside closest to the modiolus—a 
central bony core that encompasses nerve fibres from the hair cells, and blood vessels 
(Figure 1.2) (Yost, 2007). The OHCs and IHCs are divided by the pillars of Corti. 
Alongside the inner and outer hair cells are supporting cells including Deiters‘ cells, pillar 
cells, Hensen cells, Claudius cells, and Boettcher‘s (Figure 1.2) (Musiek & Baran, 2007). 
Of particular importance to the OHCs are Dieters‘ cells and Hensen cells. 
                                                             
1 However, in terms of fluid spaces, the boundary between the endolymph of scala media and the perilymph of 
scala tympani is the reticular lamina. 
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Figure 1.2: Cross section of the cochlea (Gates & Mills, 2005) 
Protruding from the apical surface of each hair cell are stereocilia—axially-directed actin-
filled microvilli with a myosin cap (McFadden, 2007). The stereocilia of the OHC only are 
embedded in the tectorial membrane. The stereocilia are arranged in rows based on 
height so that the shortest row is located on the modiolar side of the hair cell. They are 
connected via tip links which connect the tips of the shorter stereocilia to the next taller 
stereocilia, and lateral links, believed to tie adjacent stereocilia together enabling them to 
move as a unit (Pickles, Comis, & Osborne, 1984). These tip links are responsible for 
opening and closing mechanoelectrial transduction (MET) channels located near the tip 
of each stereocilia, which occurs with deflection of the hair cell bundle towards or away 
from the tallest stereocilia respectively. The deflection of the stereocilia happens in 
response to radial shearing between the reticular lamina and the tectorial membrane with 
displacement of the BM. Each time the BM moves towards scala vestibuli, the MET 
channels open and there is an influx of potassium (K+) ions from the endolymph in scala 
media into the hair cells. Movement of the BM towards scala tympani results in closure of 
the MET channels. This cyclical flow of K+ into the hair cell produces a fluctuating 
receptor current and causes cyclic changes in membrane potential. The influx of K+ into 
the inner hair cell causes the cell to depolarise and release neurotransmitter, which 
initiates an action potential in the primary afferent neurons. In addition, changes in 
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membrane potential of OHCs produces cyclical changes in cell length (Brownell, Bader, 
Bertrand, & de Ribaupierre, 1985) via the protein prestin (Liberman et al., 2002). This 
acts to cancel friction and increase the amplitude of the BM vibration by approximately 
1000-fold (or 60 dB), particularly in the higher-frequency regions of the cochlea (Patuzzi, 
2009). This mechanism is referred to as the active process and is a form of 
electromechanical (EMT) transduction (Dallos, 1992). As will be discussed below, the 
active process of the OHCs is highly vulnerable to mechanical or chemical insults, giving 
rise to primarily a high-frequency hearing loss. 
1.2 Ototoxicity 
Ototoxicity is a term used to describe the tendency of certain chemical or pharmaceutical 
agents to cause functional impairment and cellular degeneration of the inner ear and the 
eighth cranial nerve. Over 130 chemicals and drugs are reported to be potentially ototoxic 
and can result in impaired auditory and/or vestibular function (Seligmann, Podoshin, 
Ben-David, Fradis, & Goldsher, 1996). These agents are referred to as cochleotoxic and 
vestibulotoxic, respectively. Different ototoxic agents may cause damage of varying 
degrees that is either temporary or permanent (Brummett, 1980). The major groups of 
ototoxic agents described in the literature include aminoglycoside antibiotics and other 
antimicrobials, salicylates, loop diuretics, antimalarial drugs, and antineoplastic agents. 
1.2.1 Mechanisms of ototoxicity 
Cell death in the cochlea can result from both natural causes, such as the ageing process, 
and event-related trauma including exposure to intense and/or prolonged noise and 
ototoxic agents. The mechanisms behind cell death can be grouped into two general types: 
necrosis and programmed cell death (PCD), including apoptosis. 
1.2.1.1 Necrosis 
Necrotic cell death is a passive event that occurs when cells are exposed to extreme stress 
conditions which result in deregulation of normal cellular activities. This is characterised 
morphologically by extensive vacuolation of the cytoplasm, swelling of the mitochondria, 
dilation of the endoplasmic reticulum, and rupture of the plasma membrane (Artal-Sanz 
& Tavernarakis, 2005). Spillage of the cell‘s content may precipitate damage to 
neighbouring cells and initiate an inflammatory response, typically resulting in the death 
of groups of cells (Henderson, Bielefeld, Harris, & Hu, 2006). One example of necrosis in 
the cochlea is that which occurs as a result of traumatic noise exposure. 
1.2.1.2 Apoptosis 
In contrast to necrosis, apoptosis is an active process that is genetically regulated. The 
morphologic features of apoptosis include nuclear and cytoplasmic condensation, 
internucleosomal deoxyribonucleic acid (DNA) cleavage and packaging of the cell into 
apoptotic bodies that are engulfed by phagocytes, preventing release of intracellular 
components (Hengartner, 2001). Four major functional molecular groups are involved in 
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triggering and effecting the apoptosis process. These include the caspases, the adapter 
proteins, members of the tumour necrosis factor receptor (TNF-R) super family, and 
members of the B-cell lymphoma 2 (Bcl-2) family of proteins (Strasser, O'Connor, & 
Dixit, 2000). Caspases constitute a family of at least 14 cysteine proteases which 
specifically cleave after an aspartic residue in target proteins (Artal-Sanz & Tavernarakis, 
2005). Pro-apoptotic caspases contain both initiator caspases (caspase-2, caspase-8, 
caspase-9, and caspase-10) and effector or executioner caspases (caspase-3, caspase-6, 
and caspase-7) (Leist & Jäättelä, 2001). Caspases are synthesized as zymogens—an 
inactive form of an enzyme that requires a portion of its protein structure to be removed 
in order for it to be activated (Wang & Bobbin, 2007). 
There are two main pathways that can initiate the apoptotic programme — the extrinsic 
(extracellular) and the intrinsic (intracellular) route (Figure 1.3). The main extrinsic 
pathway involves the activation of receptors on the cell membrane that belong to the 
TNF-R family. These death receptors are activated by ligands and are then linked to the 
pro-caspase proteins via adapter proteins, forming the death-inducing signalling complex 
(DISC). The DISC is then able to recruit and activate the zymogens to generate the active 
initiator caspase protein, such as caspase-8, which can subsequently activate downstream 
executioner caspases, thus leading to proteolytic degradation of cellular proteins and 
apoptosis (Strasser, et al., 2000). 
The intrinsic pathway, also known as the mitochondrial pathway, accounts for the 
initiation of apoptosis in response to stimuli such as ionizing radiation, chemotherapeutic 
drugs, and certain developmental cues (Stennicke & Salvesen, 2000). It is signified by the 
release of cytochrome c, as well as changes in the transmembrane potential and 
mitochondrial permeability (T. H. Kim, Zhao, Barber, Kuharsky, & Yin, 2000).The 
mitochondrial pathway involves the Bcl-2 family of proteins. The Bcl-2 family can be 
divided into three groups, encompassing those that are pro-apoptotic (Group I) and those 
that are anti-apoptotic (Groups II and III). The pro-apoptotic groups contain Bax, Bok 
and Bak in Group II, and Bad, Bik, Bid and Bim in Group III, while the anti-apoptotic 
Group I consists of Bcl-2 and Bcl-XL (Strasser, et al., 2000). The pro-apoptotic Bcl-2 
family members such as Bax, Bak and Bid, and Bcl-2 anti-apoptotic family members 
interact at the outer membrane of the mitochondria. It is the balance of pro-apoptotic and 
anti-apoptotic components in the particular cell that determines whether or not apoptosis 
occurs. If the pro-apoptosis molecules predominate, a variety of molecules are released 
from the intermembrane mitochondrial compartment, including the primary molecule 
cytochrome c—a caspase activator. This particular protein links with the apoptotic 
protease-activating factor (Apaf-1), procaspase-9, and deoxyadenosine triphosphate 
(dATP), to form the apoptosome complex. As a result, procaspase-9 is activated (forming 
caspase-9), which in turn activates downstream effector caspases, such as caspase-3, and 
caspase-7 (Wang & Bobbin, 2007). This ultimately leads to apoptosis. 
7 
 
Figure 1.3: Illustration of the extrinsic and intrinsic apoptotic pathways (Altieri, 2003). 
1.2.1.3 Reactive oxygen species 
Reactive oxygen species (ROS) are also thought to play a role in PCD. Mitochondria serve 
as the major energy-producing powerhouses within cells, generating adenosine 
triphosphate (ATP) which is associated with the utilisation of molecular oxygen. It is 
estimated that 2 – 3% of this molecular oxygen is reduced in a one-electron fashion 
yielding a series of reactive oxygen species (Heck, Kagan, Shvedova, & Laskin, 2005). 
Free radicals are molecules with an unpaired electron in their outer orbit (Halliwell & 
Gutteridge, 1999), making them highly reactive with the potential to destabilise other 
molecules and break down molecular bonds, leading to tissue and cell damage 
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(Henderson, et al., 2006). ROS are oxygen-based molecules that either act as free radicals 
themselves or have the ability to generate free radicals. They may be produced in the 
cochlea due to high-level noise, enzymatic reactions, ischemia and reperfusion, and 
excitotoxicity (Schmidt, Knief, Lagosch, Deuster, & Zehnhoff-Dinnesen, 2008). Three 
important ROS that are generated in the reduction of O2 to H2O are the superoxide anion 
(O2
), hydrogen peroxide (H2O2) and the hydroxyl radical (OH
). The generation of these 
ROS can lead to the formation of other more damaging species, such as peroxiradicals 
(Clerici, DiMartino, & Prasad, 1995). Reactive species have been shown to be damaging to 
biologic tissues, causing lipid peroxidation, carbohydrate and protein damage, DNA 
strand breaks, and altered membrane-bound enzymes and receptors (Ghersi-Egea, 
Livertoux, Minn, Perrin, & Siest, 1991). Mitochondria respond to oxidative damage by 
neutralising free radicals via water-soluble and lipid-soluble antioxidants such as 
glutathione, ascorbate, vitamin E, and coenzyme Q, and antioxidant enzymes such as 
glutathione peroxidise, catalase, thioredoxins and peroxiredoxin (Heck, et al., 2005). 
Eventually, however, damage accumulates due to these processes being overwhelmed. 
This process is in illustrated in Figure 1.4. 
 
Figure 1.4: Illustration of the process in which free radicals are made and also managed 
by the body‘s cells (Eisen, 2000). 
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The cochlear pathology observed with exposure to ototoxic agents is typically classed as a 
motor loss, where problems are limited to the OHCs only, or a mixed loss, which involves 
disruptions to both the OHCs and IHCs, and is dependent on the particular agent 
(Patuzzi, 2009). The following section will discuss the ototoxic antineoplastic agent 
cisplatin and its effect on the cochlea. 
1.3 Cisplatin 
1.3.1 Structure 
Cis-diamminedichloroplatinum II (cisplatin; CDDP; [N2Cl2PtH6]) is a chemotherapeutic 
agent derived from the heavy metal platinum (Pt). Cisplatin originated from a discovery 
in 1965 where inhibition of the cell division process was noted in a study examining 
cultured bacteria and electrical fields using platinum electrodes (Rosenberg, Van Camp, & 
Krigas, 1965). Subsequent investigation involving mice showed platinum compounds to 
have anti-tumour activity (Rosenberg, Van Camp, Trosko, & Mansour, 1969). Cisplatin is 
a square-planar neutral platinum (II) complex consisting of a divalent Pt(II) central atom 
and four ligands of cis-positioned pairs of chlorine atoms or amine groups (Figure 1.5) 
(Rybak, Huang, et al., 2007). This unique structure of cisplatin is critical for its cytotoxic 
activity, which occurs as a result of coordinative bonds between the platinum atom and 
genomic DNA, and the formation of inter- and intra-strand crosslinks (McKeage, 1995). 
 
Figure 1.5: Structural formula for cisplatin molecule (Weiss, 2009) 
1.3.2 Clinical application 
Cisplatin is used extensively as a potent anti-neoplastic drug in the management of a wide 
variety of soft-tissue neoplasms including testicular, prostate, ovarian, endometrial, 
cervical, bladder and lung carcinoma, and SCC of the head and neck. It is also used in the 
treatment of paediatric malignancies, such as neuroblastomas, hepatoblastomas, brain 
cancer and osteosarcoma (Schmidt, et al., 2008). The toxicity profile of cisplatin is 
significant, however, and includes nephrotoxicity, gastrointestinal toxicity, peripheral 
neurotoxicity, haematological toxicity and ototoxicity. Successful modifications of 
10 
cisplatin administration involving saline hydration and mannitol diuresis have 
ameliorated nephrotoxicity, which was originally the most significant dose-limiting side 
effect (McKeage, 1995). In spite of this, ototoxicity remains a significant dose-limiting 
factor in cisplatin-based chemotherapy. Cisplatin has the highest ototoxic potential of all 
platinum compounds and is regarded as the most ototoxic agent in clinical use (Anniko & 
Sobin, 1986; Barr-Hamilton, Matheson, & Keay, 1991).There is large inter-patient 
variability in the ototoxic side effect of cisplatin. Whether this variability is a result of 
differences in drug concentrations within the inner ear or due to physiological factors is 
yet to be established. 
1.3.3 Pharmacokinetics 
Due to the significant toxicity profile of cisplatin, determining the pharmacokinetic 
parameters is very important. Consideration is given to its properties of absorption, 
distribution, metabolism, excretion and elimination (Figure 1.6). 
 
Figure 1.6: Pharmacokinetics of any given drug (Rey, 2007) 
In the body cisplatin takes two forms, one which undergoes irreversible protein binding in 
plasma, rendering it biologically inactive, and the free (unbound) potentially active form 
(Urien & Lokiec, 2004). It is this unbound form that is capable of diffusing across 
membranes and interacting with target receptors. When measuring the distribution of a 
particular drug, however, the plasma concentration is often used because accurate 
evaluation of drug concentration in tissue or organs is difficult. Investigations have shown 
that following intravenous (IV) administration of cisplatin, initial peak plasma 
concentration is 3 to >5 µg/ml (Matsumoto, 2008). The levels of cisplatin decline in a 
triphasic fashion, with an initial plasma half-life (t1/2) of 20 - 30 minutes, a second phase 
t1/2 of 60 minutes, and a terminal t1/2 of more than 24 hours (Himmelstein et al., 1981). 
Guinea pig models suggest that distribution of cisplatin to the perilymph occurs at a 
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slower rate, with the highest concentration measured at 4µg/ml 20 minutes post-
administration and a perilymph:plasma ratio at 0.40 (Laurell, Anderson, & Engström, 
1995). There was no observed accumulation in the perilymph compartment. 
1.4 Cisplatin ototoxicity 
1.4.1 Clinical features 
Cisplatin-induced ototoxicity typically manifests as irreversible, progressive, bilateral, 
high frequency SNHL associated with tinnitus (Daldal, et al., 2007). Some audiometric 
studies have reported elevated pure-tone thresholds in 75-100% of patients treated with 
cisplatin (McKeage, 1995). There is, however, significant variation in the severity of the 
loss, ranging from a loss detectable only by extended audiometric evaluation to a severe 
loss affecting communication. Cisplatin ototoxicity mainly affects the cochlea, although 
limited vestibular dysfunction has also been documented (Cass, 1991). 
The hearing loss after cisplatin exposure is most often described as symmetrical. 
Unilateral hearing loss resulting from cisplatin administration is rarely reported and is 
usually accounted for by unilateral cranial irradiation and/or surgical intervention. The 
idea that symmetrical damage to the inner ear occurs from the systemic administration of 
cisplatin is based on the assumption that the physiology of the structures is symmetrical. 
Interestingly, a recently study investigating hearing thresholds in 55 children (aged 
between 4.0 and 16.5 years) who were receiving cisplatin chemotherapy showed a small 
but significant asymmetry in behavioural thresholds at 4000, 6000 and 8000 Hz, with 
ototoxicity more pronounced in the left ear than the right (Schmidt, et al., 2008). A 
gender effect was also noted, with girls appearing less affected by the asymmetry than 
boys. The mechanisms behind this initial observation are currently unknown, however 
the author hypothesised that the asymmetry in hearing thresholds may be due to (1) 
different peripheral cisplatin effect between the ears, possibly resulting from a difference 
in cochlear blood flow; (2) supracochlear influences, such as the role of the medial 
olivocochlear system (MOCS) in the protection of the cochlea; and/or (3) the presence of 
cortical alterations due to cisplatin administration. Whether this effect also occurs in 
adults is unknown, and further research is warranted in this area. 
1.4.2 Targets of cisplatin-induced ototoxicity 
Investigations into the mechanisms and targets of cisplatin ototoxicity in the inner ear 
rely on electrophysiologic and histopathologic analysis. These methods are typically 
invasive and therefore ethically untenable in humans. As a result, what is currently known 
about the effects of cisplatin on the cochlea has been ascertained from animal models, in 
particular, guinea pigs, rats and mice. Experimental studies performed on animals have 
ascertained at least three major targets of cisplatin ototoxicity in the cochlea: the organ of 
Corti, spiral ganglion cells, and the lateral wall including the stria vascularis and spiral 
ligament. 
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Within the guinea pig organ of Corti, a wide range of cellular changes have been observed 
as early as one day after IV administration of high dose cisplatin (Laurell & Bagger-
Sjöbäck, 1991). This study documented morphological changes in the cochlea of guinea 
pigs injected with a single high dose (12.5 mg/kg) of cisplatin that occurred after one, two, 
three and four days post-cisplatin injection. Three major stages of damage to the organ of 
Corti were identified. The first stage included disturbance of the supporting cells, namely 
swelling of the Hensen‘s cells and of Dieters‘ cells with protrusion into the space of Nuel 
(Figure 1.2). The supporting cells of the IHCs appeared less vulnerable. The second stage 
was characterised by the degeneration of the OHCs, including loss of stereocilia and 
intracellular vascuolisation. In addition, vacuoles appeared below the base of the IHCs. 
This typically occurred after all the OHCs had degenerated. In the final stage, 
degeneration of the entire organ of Corti and collapse of Reissner‘s membrane was noted. 
In this final stage, damage to the IHCs ranged from changes in hair cell shape to complete 
degeneration. This overall progression of events is corroborated by other studies 
(Ramírez-Camacho, García-Berrocal, Buján, Martín-Marero, & Trinidad, 2004). 
However, results are variable with reports of Dieters and Hensen cells remaining 
unaffected by cisplatin (Dehne, Lautermann, Petrat, Rauen, & de Groot, 2001). 
In addition to the damage exerted on the organ of Corti, there is evidence that the stria 
vascularis is affected with reduction of the endocochlear potential, and elevation of the 
compound action potential and cochlear microphonic thresholds (Tsukasaki, Whitworth, 
& Rybak, 2000). Morphologically, strial damage has been noted to include oedema, 
bulging, rupture and/or compression of the marginal cells, and depletion of the 
cytoplasmic organelles (Meech, Campbell, Hughes, & Rybak, 1998). Evidence for 
cisplatin-induced degeneration of the spiral ganglion cells is limited, although 
detachment of the myelin sheaths of the type I spiral ganglion cells has been observed 
(van Ruijven, de Groot, & Smoorenburg, 2004). Further investigation (van Ruijven, de 
Groot, Klis, & Smoorenburg, 2005) attempted to time sequence these events, however, 
their examination failed to reveal any evidence of any one ototoxic process triggering 
another and thus concluded that both processes occur simultaneously and in parallel 
rather than sequentially. 
1.4.3 Mechanisms of cisplatin-induced ototoxicity 
The cellular and molecular mechanisms of cisplatin-induced ototoxicity are currently not 
well understood. A recent study by García-Berrocal et al., (2007) collected data 
supporting the involvement of the intrinsic apoptotic pathway in rat cochleae. Thirty 
female Sprague-Dawley rats were injected intraperitoneally with 5 mg kg-1 of cisplatin in 
1.0 ml of normal solution (0.9% NaCl). A further six rats were injected with only 10 ml kg-
1 0.9% NaCl to serve as a control. The thirty rats were subsequently divided into three 
groups each containing ten rats: (1) rats that were decapitated 2 days post cisplatin 
administration; (2) animals that were decapitated seven days post cisplatin 
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administration; and (3) animals that were killed thirty days after cisplatin administration. 
The remaining six rats in the control group were also divided into three groups that were 
decapitated at two days (n = 2), at seven days (n = 2) and at thirty days (n = 2). Auditory 
brainstem response (ABR) traces were recorded before cisplatin administration and again 
directly before the animals were decapitated. Immunohistochemical techniques, 
including luciferase assays and Western blotting, examined the different caspase activities 
and ATP levels in protein extracts. ABR traces showed elevated thresholds in all thirty 
rats exposed to cisplatin, although this threshold shift was only found to be significant in 
group 1 (p < 0.05). The authors reported a significant decrease in ATP levels with 
cisplatin administration, consistent with increased energy requirements of cells 
undergoing cell death by apoptosis (Eguchi, Shimizu, & Tsujimoto, 1997). In addition, 
they found evidence to support the involvement of the intrinsic apoptotic pathway, with 
cochlear extracts exhibiting progressively higher expressions of caspase-9. (Devarajan et 
al., 2002) reported cisplatin-induced apoptosis in an in vitro model system using cochlear 
half-turns from Immortomouse. Increases in both caspase-8 and caspase-9 activity were 
noted, indicating the involvement of both the death receptor mechanism (extrinsic 
pathway) as well as mitochondrial (intrinsic) pathways. In contrast, Wang et al., (2004) 
did not observe a significant increase in caspase-8 activation in cisplatin treated guinea 
pig cochleae. Furthermore, local scala tympani perfusion of a caspase-8 inhibitor (z-
IETD-fmk) was ineffective in ameliorating cisplatin-induced hair cell death and hearing 
loss. These results suggest that in vivo cisplatin-induced apoptosis of cochlear cells is 
caspase-8 independent. The authors postulated this difference may result from in vitro 
versus in vivo conditions; however, activation of caspase-3 and caspase-9 was detected. 
Perfusion of their respective inhibitors, z-DEVD-fmk and z-LEHD-fmk, significantly 
reduced DNA fragmentation, hair cell death and hearing loss. Overall, the literature 
indicates the cisplatin-induced ototoxicity is mediated through the intrinsic apoptotic 
pathway (Wang & Bobbin, 2007). 
In conjunction, evidence has arisen accumulated from numerous studies implicating ROS 
in the destruction of sensory cells in the cochlea (Mukherjea et al., 2006). Cisplatin 
administration has been shown to result in depletion of glutathione and antioxidant 
enzymes (superoxide dismutase, catalase, glutathione peroxidise and glutathione 
reductase) in cochlear tissues, with an equivalent increase in malondialdehyde levels 
(Rybak, Husain, Morris, Whitworth, & Somani, 2000). This decrease in glutathione levels 
is thought to indicate the formation of ROS in cisplatin oto- and nephrotoxicity (Husain 
et al., 1998). Exposure to cisplatin generates the superoxide anion which, although not 
highly toxic itself, can transform into hydrogen peroxide and subsequently into the highly 
reactive hydroxyl radical as a result of catalysis by iron (the Fenton reaction). The 
hydroxyl radical is then free to react with all biological macromolecules and 
polyunsaturated fatty acids, generating the toxic aldehyde 4-hydroxynonenal (4-HNE) 
through lipid peroxidation (Figure 1.7). Findings by Lee et al., (2004) suggest hair cell 
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degeneration is in part due to the hydroxyl radical, indicating that iron plays an important 
role in cisplatin ototoxicity (Dehne, et al., 2001). Exposure to ROS can induce apoptosis 
(Wang & Bobbin, 2007). 
 
Figure 1.7: Diagram of the generation of highly reactive radical species. SOD – superoxide 
dismutase (J. E. Lee, et al., 2004) 
1.4.4 Risk factors 
There appears to be substantial variation in human susceptibility to cisplatin-induced 
ototoxicity possibly as a result of treatment and patient-related factors, such as 
cumulative dose, age, renal dysfunction, cranial irradiation and diet. Each of these factors 
is discussed below. 
1.4.4.1 Cumulative dose 
A number of studies have investigated the effect of cumulative cisplatin dose on observed 
ototoxicity, particularly cumulative doses greater than 400 mg/m2. Li, Womer & Silber 
(2004) examined pure-tone audiograms from 153 children, ranging in age from 6 months 
to 18 years, who had received cisplatin therapy at doses of 40 to 200 mg/m2/cycle. The 
risk of developing bilateral moderate to severe high-frequency hearing loss was 
significantly related to individual and cumulative cisplatin dosage (both p < 0.005). This 
is supported by Brock, Bellman, Yeomans, Pinkerton and Pritchard(1991) who 
retrospectively assessed 29 children who had been treated with 60 - 100 mg/m2/cycle 
cisplatin. The risk of developing ototoxicity increased significantly with the cumulative 
dose (p = 0.027). No evidence of hearing loss was found in children who received a 
cumulative dose less than 400 mg/m2. 
1.4.4.2 Age 
Research suggests that cisplatin-induced ototoxicity is age-dependent, with increased 
susceptibility of young children and older adults. Li, et al., (2004) demonstrated that 
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children younger than five years of age at the time of treatment are more likely to 
experience cisplatin-induced ototoxicity than their older peers. A logistic regression 
model predicts that approximately 40% of the children younger than 5 years would 
develop moderate to severe losses when they receive a cumulative dose of 400 mg/m2, 
compared with the 5% risk among children between 15 and 20 years of age. This 
translates into an average of an eight-fold increase in relative risk. Helson, Okonkwo, 
Anton and Cvitkovic (1978) observed that hearing loss was more severe in patients aged 8 
to 20 years, or older than 46 years of age, who received a cumulative dose greater than 
400 mg/m2 than in patients aged 21 to 45 years receiving the same dosage. 
1.4.4.3 Renal dysfunction 
Given the role of the kidneys in the clearance of cisplatin, renal function measured by 
serum creatinine levels is of significance. A study by Bokemeyer et al., (1998) examined 
various aspects of ototoxicity in 86 patients who had been in complete remission for at 
least 12 months. Information regarding previous auditory symptoms, potential risk 
factors and treatment variables was collected. Serum creatinine levels were measured 
prior to cisplatin administration and showed that patients with higher levels (92 µmol 1-1) 
were significantly more likely to report persisting ototoxic symptoms that patients with 
lower levels (83 µmol 1-1) (P = 0.04). This observation is in accordance with reports from 
(Schaefer, Post, Close, & Wright, 1985). Patients with renal insufficiency (poor renal 
creatinine clearance) are at greater risk of ototoxicity due to increased serum active 
cisplatin levels (Rybak, 2007). 
1.4.4.4 Noise 
Bokemeyer et al., (1998) also examined noise exposure as a risk factor. A history of noise 
exposure was independently correlated to both persisting ototoxic symptoms (P = 0.006) 
and to audiometrically verified hearing loss (P = 0.04). Seven of 15 (47%) patients with 
previous noise exposure, compared with 10 of 66 (15%) patients without a history of noise 
exposure, complained about ototoxic symptoms. This showed a 3.1-fold increased relative 
risk for ototoxicity in patients with a history of noise exposure. 
1.4.4.5 Cranial irradiation 
Cranial irradiation is a risk factor that is particularly pertinent to this study. Hearing loss 
is a relatively common complication of irradiation to the head and neck area (Honoré, 
Bentzen, Møller, & Grau, 2002; Raaijmakers & Engelen, 2002; Talmi, Finkelstein, & 
Zohar, 1989). Irradiation can cause two kinds of hearing impairment; conductive hearing 
loss (such as otitis media) and SNHL (Honoré, et al., 2002). A systematic review of the 
literature yielded substantial variability in the reported incidence of SNHL resulting from 
irradiation alone, ranging from 0% to 50% (Raaijmakers & Engelen, 2002). The authors 
concluded that at least one out of three patients receiving a standard dose of 70 Gy in 2 
Gy per fraction near the inner ear can be expected to develop hearing loss of 10 dB or 
more at 4 kHz. When in combination with cisplatin treatment, an increase in risk was 
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noted (Low, Toh, Wee, Fook-Chong, & Wang, 2006). Hearing thresholds in patients 
receiving 25 mg/m2/day cisplatin for four days and 70 Gy in 2 Gy per fraction irradiation 
(n = 58) were significantly poorer (p = 0.001) when compared with those receiving 
irradiation alone (n = 57) (Low, et al., 2006). 
1.4.4.6 Diet 
A study investigating the effect of dietary factors on cisplatin ototoxicity in guinea pigs 
found a correlation between low-protein diets and severity of hearing loss (Lautermann, 
Song, McLaren, & Schacht, 1995). Four experimental groups of pigmented, adult male 
guinea pigs were maintained either on a regular guinea pig diet (18.5% protein) or a low 
protein diet (7% protein) for two weeks before the start of drug treatment. The groups 
consisted of: (1) a control group with 9 guinea pigs on the full protein diet; (2) 9 guinea 
pigs on the low protein diet; (3) 18 animals in the cisplatin-treated group on the full 
protein diet; and (4) 22 animals in the cisplatin-treated group on the low protein diet. 
Cisplatin (1 mg/kg) was injected subcutaneously into animals in groups 3 and 4 for 12 
consecutive days. Every other day the animals were weighed and the dose of cisplatin 
adjusted accordingly. ABR recordings were obtained from all groups at the beginning of 
the study and on experimental days 13 and 15. Serum platinum, serum albumin, blood 
urea nitrogen (BUN) and creatine levels were ascertained in addition to glutathione levels 
in the tissue. Results showed that the control animals on either diet did not develop any 
hearing loss. The guinea pigs fed on the full protein diet (group 3) displayed minimal 
hearing loss (9 ± 6 dB at 8 kHz, and 10 ± 9 dB at 18 kHz), while guinea pigs on the low 
protein diet (group 4) displayed significantly greater hearing loss (23 ± 17 dB at 8 kHz, 
and 32 ± 23 dB at 18 kHz) (p < 0.005). Glutathione levels in the control animals on a low 
protein diet were half that of those on a full protein diet. The addition of cisplatin, 
however, did not seem to decrease these levels any further. The mean values of serum 
albumin and serum platinum levels were not statistically significant between the four 
groups. BUN levels were significantly reduced by the low protein diet (group 2), while 
treatment with cisplatin elevated BUN in both group 3 and 4. In contrast, creatine levels 
remained unaffected by diet but increased in response to cisplatin treatment. The authors 
concluded that the severity of ototoxicity is influenced by dietary factors. This finding is in 
agreement with clinical studies that have associated cisplatin ototoxicity with patient‘s 
general health (Blakley, Gupta, Myers, & Schwan, 1994). 
1.4.5 Protection against cisplatin-induced ototoxicity 
The cochlea is thought to have endogenous cytoprotective responses to injury that may 
arise from, for example, oxidative stress resulting from cisplatin exposure. The 
cytoprotective responses involve many molecules, including glutathione and the 
antioxidant enzymes, heat shock proteins, adenosine A1 receptors, NRF2 and heme-
oxygenase-1, and the kidney injury molecule (KIM-1) (Mukherjea, et al., 2006). High 
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concentrations of ROS, however, may overwhelm this regenerative process and lead to 
cell death. 
In current clinical practice, cisplatin-induced ototoxicity is tolerated as a side-effect of 
cancer treatment. Numerous agents have been investigated for their protective properties 
against cisplatin-mediated damage in the cochlea and include both upstream and 
downstream protection (Table 1.1). Due to concerns regarding potential interference with 
the anti-tumour effect of cisplatin, there are currently no otoprotective agents approved 
for use in humans by the Food and Drug Administration (FDA) or Medsafe. The following 
section will discuss the various agents that have been investigated for protecting the 
cochlea against cisplatin-induced ototoxicity. 
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Table 1.1. Effects of protective agents against cisplatin ototoxicity (adapted from Rybak & Whitworth, 2005) 
Agent Mechanism In vivoa In vitrob Species 
Degree of 
protection
c
 
Thiosulfate Upstream chelator Cochlear perfusion  Guinea pig +++ 
Thiosulfate Upstream chelator Chronic round window  Guinea pig 0 
Amifostine Upstream chelator i.p  Hamster +++ 
Glutathione ester Antioxidant i.p  Rat + 
Diethyldithiocarbamate Upstream chelator i.p  Rat ++ 
Methylthiobenzoic acid Upstream chelator i.p  Rat ++ 
Ebselen  i.p  Rat +++ 
Ebselen & Allopurinol  p.o  Rat ++ 
Salicylate Antioxidant s.c  Rat ++ 
Salicylate Antioxidant s.c  Rat +++ 
α - Tocopherol Antioxidant i.p  Rat ++ 
α - Tocopherol Antioxidant i.p  Guinea pig ++ 
Trolox Antioxidant Round window  Guinea pig ++ 
α - Tocopherol + tiopronin Upstream chelator and antioxidant i.p  Guinea pig ++ 
Tiopronin Upstream chelator i.p  Rat ++ 
Aminoguanidine Inhibits iNOS i.p  Rat ++ 
R-PIA Increases antioxidant concentrations Round window  Chinchilla ++ 
CCPA Adenosine receptor modifier Round window  Chinchilla ++ 
Z-DEVD-fluoromethyl ketone 
(caspase-3 inhibitor) 
Downstream apoptosis prevention Cochlear perfusion  Guinea pig +++ 
Z-LEKD-fluoromethyl ketone 
(caspase-9 inhibitor) 
Downstream apoptosis prevention Cochlear perfusion  Guinea pig +++ 
Pifithrin   X  ++ 
D-JNKI 1 Downstream apoptosis prevention Cochlear perfusion  Guinea pig 0 
M40403   X  0 
D-methionine Prevents antioxidant enzyme depletion i.p  Rat +++ 
 
a Abbreviations: i.p., intraperitoneal; p.o., per os; s.c., subcutaneous. 
b Key: X denotes that in vitro studies have been carried out. 
c Key: +, low efficacy; ++, moderate efficacy; +++, high efficacy 
19 
Otoprotective agents can be classed as either upstream protectors or downstream 
protectors. 
1.4.5.1 Upstream protection 
One strategy to protect the cochlea from cisplatin-induced ototoxicity is the 
administration of antioxidant drugs. Antioxidants are chemicals that protect cellular 
components from the oxidative damage caused by free radicals and other reactive oxygen 
species. Antioxidants are thought to provide upstream protection by preventing the 
initiation of cell death in the cochlea (Rybak, Whitworth, Mukherjea, & Ramkumar, 
2007). A variety of antioxidant compounds have been tested against cisplatin-induced 
ototoxicity, several of which contain thiol groups. The effectiveness of this group is based 
on the high affinity of sulphur for platinum (Campbell & Rybak, 2007). Sodium 
thiosulfate (STS) is thought to neutralise cisplatin by forming an inactive platinum-
thiosulfate complex that is excreted by the kidney, reducing its ototoxic and 
chemotherapeutic properties (Wimmer et al., 2004). Wang, et al., (2003) investigated 
direct application of STS to the cochlea through perilymphatic perfusion. Twelve guinea 
pigs were divided into two groups and fitted with an osmotic minipump to their right 
cochlea containing either (1) artificial perilymph (n = 6), or (2) 10 mM STS (n = 6). After 
two days, all 12 guinea pigs received intraperitoneal injections of 2 mg/kg/day cisplatin 
for 5 consecutive days. Audiograms were derived from the compound action potential 
(CAP) for both ears daily and distortion product otoacoustic emissions (DPOAEs) were 
measured at the end of the treatment period. Guinea pigs that received a perfusion of 
artificial perilymph experienced hearing loss in both the left and right ear, consistent with 
cisplatin-induced ototoxicity. In contrast, guinea pigs that received a perfusion of STS 
showed a statistically significant difference between the left ear and the right ear (P < 
0.01). DPOAE results remained unchanged in the right ear. Histological analysis revealed 
minimal loss of OHC in the organ of Corti and no damage to the marginal cells of the stria 
vascularis. Furthermore, it prevented cisplatin-induced mitochondrial damage by 
suppressing apoptotic and necrotic hair cell degeneration. Although effective, it is unlikely 
that this highly invasive route would be considered for routine use in humans. Similar 
research by Wimmer, et al.,(2004) found no protection against cisplatin-induced 
ototoxicity when STS was applied to the round window membrane. Potential reasons for 
this include insufficient dose of STS relative to the higher dose of cisplatin used in the 
latter study, or problems with the placement of the round window catheter (Rybak, 
Whitworth, et al., 2007). Another member of the thiol group, D-Methionine (D-Met), has 
also been investigated for protection against cisplatin-induced hearing loss, OHC loss and 
damage to the stria vascularis in rat cochleae, with promising results (Campbell, Meech, 
Rybak, & Hughes, 1999; Campbell, Rybak, Meech, & Hughes, 1996; Meech, et al., 1998). 
D-Met is advantageous in that it does not interfere with the tumouricidal action of 
cisplatin (Rybak, Whitworth, et al., 2007). α-tocopherol (vitamin E), a slow-acting free 
radical scavenger is another antioxidant that appears to have a protective effect against 
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cisplatin ototoxicity in both rats (Kalkanis, Whitworth, & Rybak, 2004) and guinea pigs 
(Teranishi, Nakashima, & Wakabayashi, 2001). α-tocopherol can scavenge the highly 
reactive hydroxyl radical preventing lipid peroxidation (Figure 1.8). 
 
 
Figure 1.8: Illustration of defence mechanisms against damage by ROS. Iron chelators 
bind to iron ions and minimise the formation of the hydroxyl radical. Α-tocopherol acts as 
a radical scavenger of the hydroxyl radical. SOD – superoxide dismutase (J. E. Lee, et al., 
2004). 
Another agent that provides upstream protection is tiopronin. Intraperitoneal injections 
of tiopronin have been shown to exert a protective effect on the rat cochlea (Fetoni et al., 
2004). Twenty-four adult Wistar rats were divided into three equal groups: (1) those who 
received saline only; (2) those who received 2 mg/kg cisplatin injections; and (3) those 
who received 2 mg/kg cisplatin and 300 mg/kg tiopronin. Dosage was repeated for eight 
consecutive days. Cochlear function was measured by DPOAEs before treatment and on 
the fourth and ninth day post-injection. DPOAE responses were significantly reduced in 
group 2 compared to the controls (group 1) (p < 0.05) while DPOAE responses from 
group 3 were significantly increased compared to those obtained with cisplatin 
administration alone (p < 0.05). Electron microscopy of the cochlea showed that 
tiopronin had a significant protective effect on the basal half and in the middle of the 
lower turn of the cochlear. 
Glucocorticoids are a class of drugs that have shown promising results as an 
otoprotectant, also functioning as an upstream protector. Nagura et al., (1999) examined 
the effect of one glucocorticoid, hydrocortisone, on impaired cochlear blood flow induced 
by ROS in guinea pigs. Cochlear microcirculatory disorders were induced by 
photochemical reactions. Hartley guinea pigs were divided into the following five groups: 
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(1) those who received 0.8 ml/kg of saline (n = 6), (2) those who received 600 mg/kg of 
amidotriziate (n = 6), (3) those who received 4 mg/kg of ATP (n = 6), (4) those who 
received 50 mg/kg of hydrocortisone (n = 5), and (5) those who received 100 mg/kg of 
hydrocortisone (n = 5). The drugs were administered by IV infusion 10 minutes prior to 
the start of the photochemical reaction. Cochlear blood flow was continuously measured 
with a non-contact laser flowmeter for 30 minutes. Of the three drugs tested, 
hydrocortisone was found to be the most effective in attenuating the impairment of 
cochlear blood flow and cochlear vascular conductance. It was found to have significantly 
prevented a decrease in the cochlear blood flow (p < 0.05) in a dose dependent manner, 
and reduced the size of the degenerated portion of the stria vascularis (p < 0.01). These 
observations support the hypothesis that hydrocortisone has therapeutic potential for 
improving tissue inflammation of the cochlea induced by ROS. This is in agreement with 
previous research that reported hydrocortisone as a non-enzymatic antioxidant that can 
prevent lipid perioxidation (Otamiri, 1989). Subsequent research has shown another 
glucocorticoid, dexamethasone, to significantly reduce aminoglycoside ototoxicity in 
guinea pigs (Himeno et al., 2002) and chinchillas (Park, Choi, Russell, John, & Jung, 
2004), presumably by inhibiting the synthesis of nitric oxide and free radical formation. 
This may be significant, as aminoglycoside ototoxicity is thought to have a similar 
pathogenesis to cisplatin ototoxicity. However, corticosteroids, such as dexamethasone, 
have also been shown to down-regulate apoptosis genes in tumour cells (Herr et al., 
2003). This raises concern that systemic administration may decrease the efficacy of 
cisplatin‘s anti-tumour properties. In addition, prolonged administration of high-dose 
oral corticosteroids have been associated with serious adverse side-effects including bone 
fractures, osteoporosis, susceptibility to infections, hyperglycaemia and weight gain 
(Manson, Brown, Cerulli, & Vidaurre, 2009). 
The systemic administration of corticosteroids, such as dexamethasone, is currently used 
extensively in the management of a number of inner ear disorders including autoimmune 
disease, idiopathic sudden SNHL, acute postmeningitic labyrinthitis and Cogan‘s 
syndrome. Intratympanic (IT) administration of drugs is a contemporary method used in 
the treatment of the disorders listed above and allows a much higher concentration of 
drug within the inner ear when compared to oral or parenteral routes (Bird, Begg, Zhang, 
Keast, & Murray, 2007). Other advantages may include avoidance of common side-effects 
associated with systemic steroids. Potential disadvantages, however, may include pain, 
chronic tympanic membrane perforation, acute otitis media, otorrhea, vertigo, and the 
possibility of further deterioration in hearing (Haynes, O'Malley, Cohen, Watford, & 
Labadie, 2007). Pharmacokinetic profiles of dexamethasone in guinea pig models showed 
elevated perilymph concentrations at > 5 mg/L for six hours following round window 
membrane administration and placement of a saturated gel foam pad within the middle 
ear for 45 minutes (Yang et al., 2008). The human model showed peak concentration of 
20 mg/L with variability in half-life (t1/2) between 13.5 and 27 minutes (Bird, et al., 2007). 
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Daldal et al., (2007) investigated the protective effect of IT dexamethasone on cisplatin-
induced ototoxicity in 24 adult female guinea pigs. The animals were divided into four 
groups: those exposed to (1) cisplatin only, (2) IT dexamethasone only, (3) cisplatin and 
IT dexamethasone, and (4) cisplatin and IT saline. Cochlear function was assessed using 
DPOAEs. Group 1 experienced statistically significant decreases of both DPOAE 
amplitude and signal to noise ratio (SNR) (p = 0.002). Groups 2 and 4 showed no 
significant difference (p > 0.05), indicating that intratympanic dexamethasone and saline 
had no toxic effect on cochlear emissions in this study. Of particular importance are the 
results from group 3 that showed no significant differences between DPOAE amplitudes 
and SNR values before and after cisplatin treatment for those who also had 
dexamethasone injections (p > 0.05). This was further investigated by Hill, Morest and 
Parham (2008) who conducted a three phase trial using female CBA/J mice. Pre-
treatment ABRs were obtained in ten mice. On day one each mouse received IT 
dexamethasone (24 mg/ml) in one ear and IT 0.9% saline in the contralateral ear, serving 
as a control. The mice were divided so that five of the mice received dexamethasone 
injections in the left ear and saline in the right, whereas the other five received the 
dexamethasone to the right ear and saline in the left. Following the initial IT injections, all 
mice were administered 14 mg/kg intraperitoneal cisplatin. IT dexamethasone and saline 
injections were repeated on days two to five. Post-treatment ABR was performed on day 
eight. There was a 20% mortality rate observed and one case of otitis media in a 
dexamethasone-treated ear which was excluded from the analysis. ABR traces from the 
remaining seven dexamethasone-treated ears and the eight saline-treated ears were 
compared. Average click-evoked ABR thresholds were elevated by 14 ± 6 dB for ears 
treated with IT saline, whereas ears treated with IT dexamethasone had a minimal 
average click-evoked ABR threshold shift of 2 ± 2 dB (p = 0.0005). A similar result was 
obtained with pure-tone evoked ABR at 8 kHz (p = 0.03) and 16 kHz (p = 0.002). There 
was, however, no significant difference observed between dexamethasone and saline-
treated ears at 32 kHz (p = 0.8). The authors speculate this may be due to decreased 
efficacy at the basal turn of the cochlea where there is increased susceptibility to cisplatin 
ototoxicity. Overall, these results support those found by Daldal et al., (2007) that IT 
dexamethasone appears to play a protective role against cisplatin-induced ototoxicity. To 
the best of our knowledge, these findings have not yet been replicated in humans. 
1.4.5.2 Downstream protection 
Downstream protection has been investigated less frequently than upstream protection. 
Downstream protection against cisplatin-induced ototoxicity in guinea pigs has been 
achieved with intracochlear perfusion of caspase-3 inhibitor (z-DEVD-fmk) and caspase-9 
inhibitor (z-LEHD-fmk) (Wang, et al., 2004). Both agents have dramatically reduced the 
incidence of hearing loss, apoptosis and hair cell loss, although, the method of 
administration is invasive and therefore may not be appropriate for use in patients. 
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1.5 Audiologic assessment & monitoring 
Hearing loss can result in significant vocational, educational and social consequences. 
Risk factors for developing hearing loss from ototoxic agents have been identified, 
although these are highly variable. Hearing loss from ototoxicity can be minimised or 
prevented if detection is timely and intervention appropriate, such as modifying the dose 
of the ototoxic drug or changing to an alternative, less ototoxic therapy. For this to occur, 
a stringent protocol is required, involving the coordination and education of a number of 
health professionals. One aim of the present study was to determine the extent to which 
this has been happening at Christchurch Public Hospital, in New Zealand. 
One of the largest governing bodies for audiologists, the American Speech-Language-
Hearing Association (ASHA), formed an Ad Hoc Committee on Audiologic Management 
of Individuals Receiving Ototoxic and/or Vestibulotoxic Drug Therapy and subsequently 
developed ―Guidelines for the audiologic management of individuals receiving 
cochleotoxic drug therapy‖ (American Speech-Language-Hearing Association, 1994). In 
it, they outlined six fundamental elements of a cochleotoxicity monitoring programme: (1) 
specific criteria for identification of toxicity; (2) timely identification of at-risk patients; 
(3) pre-treatment counselling regarding potential cochleotoxic effects; (4) valid baseline 
measures (pre-treatment or early in treatment); (5) monitoring evaluations at sufficient 
intervals to document progression of hearing loss or fluctuation in sensitivity; and (6) 
follow-up evaluations to determine post treatment effects. Each of these fundamental 
elements is outlined below. 
1.5.1 Basic principles of cochleotoxicity monitoring 
1.5.1.1 ASHA criteria for cochleotoxicity 
Determining whether ototoxicity has occurred clinically is achieved by comparing results 
of audiometric tests to baseline data obtained prior to the beginning of treatment. This 
method takes into account the patient‘s previous hearing status, thus serving as their own 
control. ASHA (American Speech-Language-Hearing Association, 1994) defines clinically 
significant changes in pure-tone thresholds as: (1) ≥ 20 dB decrease at any one test 
frequency; (2) ≥ 10 dB decrease at any two adjacent test frequencies; or (3) loss of 
response at three consecutive test frequencies where responses were previously obtained. 
These thresholds must be confirmed by a repeat assessment. The third criterion refers 
specifically to the highest frequencies tested, where previous responses were obtained 
close to the limits of the audiometer. Criteria for clinically significant changes in 
threshold must be sensitive and specific to minimise rates of false positives and false 
negatives. Test-retest reliability for behavioural pure-tone thresholds is reported to be ± 
10 dB for the frequency range 0.5 – 16 kHz (Frank, 2001; Schmuziger, Probst, & 
Smurzynski, 2004), while threshold shifts at two adjacent frequencies are thought to 
24 
better represent an actual change in hearing sensitivity rather than normal variation 
(Pasic & Dobie, 1991). 
1.5.1.2 Patient identification 
ASHA (American Speech-Language-Hearing Association, 1994) recommends all patients 
receiving treatment with drugs known or suspected to have cochleotoxic properties 
should undergo monitoring as part of a protocol that is implemented in a timely manner. 
For this to occur, it requires access to a registry of patients (both inpatients and 
outpatients) who are being treated with potentially cochleotoxic medication, and effective 
communication and cooperation between audiology, oncology, nursing and hospital 
pharmacy personnel. Patients who are likely to be particularly susceptible to ototoxicity 
should also be identified. These include very young patients (Li, et al., 2004), those with 
poor renal function (Rybak, Huang, et al., 2007) and those prescribed prior or concurrent 
cranial irradiation (Honoré, et al., 2002; Raaijmakers & Engelen, 2002). 
1.5.1.3 Pre-treatment counselling 
Prior to patients undergoing medical treatment with cochleotoxic drugs, appropriate 
counselling should be utilised. Fausti et al., (2007) suggests three different phases of 
patient counselling by the audiologist: (1) initiating contact with and educating the 
patient about potentially ototoxic medications; (2) counselling the patient about possible 
hearing changes and post-treatment rehabilitation; and (3) emphasising the importance 
of hearing protection during and following therapeutic treatment. Patients should be 
encouraged to report symptoms such as tinnitus, aural fullness, loss of balance, and 
changes in hearing sensitivity to their physician if they occur. 
1.5.1.4 Baseline testing 
Obtaining accurate baseline data is crucial for the successful monitoring of patients 
receiving ototoxic medication. As cisplatin can cause measureable hearing loss following 
administration of a single dose, ASHA (American Speech-Language-Hearing Association, 
1994) recommends that a baseline evaluation should preferably be carried out prior to the 
first dose of cisplatin, and no later than 24 hours after. Testing should begin with a 
comprehensive case history, ascertaining the presence of any current auditory and 
vestibular symptoms, details of previous noise exposure and prior exposure to ototoxic 
medication. In addition, Fausti et al., (2007) recommend that a form of tinnitus 
evaluation is administered such as the Tinnitus Ototoxicity Monitoring Interview (TOMI) 
(Table 1.2). This was designed to document tinnitus onset and any perceptual changes 
that occur during the monitoring phase. The rest of the baseline evaluation should include 
otoscopy, tympanometry, acoustic reflexes to assess the status of the middle ear, and 
pure-tone audiometry to obtain air conduction thresholds at 0.5, 1, 2, 3, 4, 6, 8, 9, 10, 11.2, 
12.5, 14, 16, 18, and 20 kHz bilaterally. Bone conduction thresholds should also be 
obtained at 0.5, 1, 2 and 4 kHz in order to identify any conductive pathology. A test of 
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speech discrimination should also be included. Lastly, an objective measure should be 
employed, such as DPOAEs. 
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Table 1.2 The Tinnitus Ototoxicity Monitoring Interview (TOMI) (Fausti, et al., 2007) 
You are being treated with a medication that has the potential to affect the auditory system. 
One possible effect is tinnitus, which is ringing, humming, buzzing, or other noises in your 
ears or head. 
1. [Clinician: ask only at the first visit] 
Did you have persistent tinnitus before 
the start of treatment? 
 No  Yes 
1a. If yes, how long have you had 
tinnitus? 
 Less than 1 
year 
 1-2 years  3-5 years 
  6-10 years  11-20 years  More than 
20 years 
  Not sure   
2. Have you noticed any persistent 
tinnitus since you started the treatment? 
 No  Yes 
 If no, the interview is complete. No further 
questions are required. 
 If Yes, continue to question 3. 
3. What does your tinnitus sound like? 
(Mark all that apply) 
 Ringing  Hissing  Buzzing  Sizzling 
  Crickets  Whistle  Hum  
  Other: 
4. Does your tinnitus have a pulsing 
quality to it? 
 No  Yes 
5. Where is your tinnitus located?  Left ear only  Right ear only 
  Both ears  Inside head 
  Other: 
6. Is your tinnitus louder on one side of 
your head than the other? 
 Right is louder than 
left 
 
  Left is louder than 
right 
 Equal 
7. How loud is your tinnitus on average?  Not loud at 
all 
 Slightly loud  Moderately 
loud 
  Very loud  Extremely 
loud 
 
8. How much of the time do you think 
your tinnitus is present? 
 Occasionally  Some of the time 
  Most of the time  Always 
9. On average, how much of a problem is 
your tinnitus? 
 Not a 
problem 
 Slight 
problem 
 Moderate 
problem 
  Big 
problem 
 Very big 
problem 
 
[Clinician: Ask the following questions only if the patient (1) had tinnitus before the start of 
treatment, or (2) reported tinnitus previously with this TOMI. The objective is to determine if 
the patient‘s tinnitus is being affected by the drug treatment. If the patient has previously 
responded to this interview, each response should reflect the period of time since the last 
interview. Otherwise, each response reflects the period of time since before the start of 
treatment. 
10. Has the sound of your tinnitus 
changed? 
 No  Yes  Not sure 
 If yes, how is it different? 
11. Has the location of your tinnitus 
changed? 
 No  Yes  Not sure 
 If yes, how is it different? 
12. Has the loudness of your tinnitus 
changed? 
 No  Yes, louder now 
  Yes, quieter now  Not sure 
13. Has the amount of time your tinnitus 
is present changed? 
 No  Yes, more often 
  Yes, less often  Not sure 
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1.5.1.5 Monitoring schedule 
Monitoring assessments should be scheduled at intervals that will allow the earliest 
possible detection of cochlear damage, ideally before conventional frequencies are 
affected so as to preserve speech perception (Jacob, Aguiar, Tomiasi, Tschoeke, & de 
Bitencourt, 2006). Appropriate time intervals may vary depending on the type of cancer 
and frequency and dose of cochleotoxic medication. 
1.5.1.6 Follow-up evaluations 
The purpose of follow up evaluation is to detect post-treatment cochleotoxicity and/or to 
document any recovery in hearing sensitivity. Fausti et al., (2007) recommends that 
testing be conducted at one month and three months after the cessation of treatment with 
the potentially ototoxic agent. At six months post-treatment a repeat assessment should 
be carried out to assess the patient‘s overall hearing health. Rehabilitative counselling 
may also be appropriate depending on test outcomes. 
1.5.2 Measures of ototoxicity 
1.5.2.1 Pure-tone audiometry 
Cisplatin ototoxicity is well documented to cause initial damage in the basal turn of the 
cochlea, thus affecting high frequencies before progressing to affect lower frequencies. 
Consequently, a number of studies have demonstrated extended high-frequency (EHF) 
audiometry (> 8 kHz) to have increased sensitivity over conventional audiometry (≤ 8 
kHz) in the early detection of ototoxicity (Dreschler, Hulst, Tange, & Urbanus, 1989; 
Fausti, Frey, Henry, Olson, & Schaffer, 1993; Knight, Kraemer, Winter, & Neuwelt, 2007; 
Ress et al., 1999). Identifying hearing loss before damage occurs at conventional 
frequencies may allow the preservation of hearing at frequencies most important for 
speech understanding and communication, thus reducing the impact on individuals‘ 
quality of life. 
The use of continuous versus pulsed tones in EHF audiometry has been investigated. It 
has been noted that relative to continuous tones, pulsed tones decrease the number of 
false positives in both normal hearing listeners and listeners with SNHL with tinnitus 
(Mineau & Schlauch, 1997). There appears to be no significant difference in thresholds 
obtained using the two stimuli in normal listeners from 10 to 16 kHz (Hamill & Haas, 
1986). More recently, Burk and Wiley (2004) found a preference for pulsed tones, 
particularly under more difficult listening situations such as low intensity and high 
frequency tones. This preference did not adversely affect the test‘s outcome and, in 
combination with the previous observations, supports the use of pulsed tones in EHF 
audiometry (Figure 1.9). 
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Figure 1.9: Illustration of a continuous pure-tone stimulus versus a pulsed tone stimulus 
1.5.2.2 Otoacoustic emissions 
OAEs provide a non-invasive objective measure of cochlear function. OAEs consist of 
acoustic energy produced by the cochlea that is recorded in the EAC, and are thought to 
result from electromechanical transduction by the OHCs of the cochlea (Kemp, 1978). 
OAEs can be observed via a number of different modes, commonly referred to as ‗types‘ of 
OAEs (Kemp, 2008). These types include spontaneous otoacoustic emissions (SOAEs), 
stimulus frequency otoacoustic emissions (SFOAEs), transient-evoked otoacoustic 
emissions (TEOAEs), and DPOAEs. For the purpose of ototoxicity monitoring, DPOAEs 
have been found to be more effective than TEOAEs which elicit a broad band cochlear 
response (Schmidt, et al., 2008). DPOAEs are particularly valuable for monitoring 
ototoxicity in patients who are unable to provide reliable behavioural thresholds due to 
age (Knight, et al., 2007) or illness (Reavis et al., 2008). 
The non-linearity of the cochlea is an essential component of cochlear function. One 
aspect of this non-linear phenomenon is distortion, the output of energy that is not 
present in the eliciting input frequencies (Prieve & Fitzgerald, 2002). DPOAEs are one 
result of this non-linear behaviour. The frequency of the distortion product is 
mathematically related to the frequencies of the two primary stimuli, f1 and f2. Although 
DPOAEs are produced at various frequencies, the largest amplitude response in humans 
is described by 2f1 – f2 (Probst, Lonsbury-Martin, & Martin, 1991). 
In the measurement of DPOAEs, two stimulus tones are applied which are normally less 
than half an octave apart. The presence or absence of DPOAEs is determined statistically 
by identifying the level of the response above the level of background noise at 
neighbouring frequencies (Kemp, 2008), commonly referred to as the signal-to-noise 
ratio (SNR). For behavioural thresholds up to 20 dB HL, DPOAEs typically have a SNR of 
greater than 5 dB (Hall, 2000), although OAEs are usually absent or significantly reduced 
when hearing thresholds are greater than 40 to 50 dB HL in cases of SNHL (Gorga, Neely, 
Dorn, & Hoover, 1997; Harris, 1990). The reliability, specificity and sensitivity of DPOAEs 
are generally high, with studies reporting sensitivity from 94% (Harris, 1990) to 100% 
(Gorga, Neely, & Dorn, 1999). OAEs were not in widespread clinical use when the specific 
ototoxicity guidelines were stipulated by ASHA, and therefore do not form a part of the 
test battery. 
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1.5.2.3 Tinnitus 
Tinnitus is defined as the sensation of sound in the absence of exogenous stimuli (Lustig, 
2010). Tinnitus can be divided into two general categories: objective and subjective 
tinnitus. Objective tinnitus is thought to originate from internally generated sounds that 
reach the ear via conduction in body tissues, and can be recorded objectively with a 
microphone or heard by another listener. Subjective tinnitus is thought of as a symptom 
with multiple aetiologies (McCombe et al., 2001). It has been associated with various 
forms of hearing loss including noise-induced hearing loss, presbycusis, and drug-
induced ototoxicity. Many of the major groups of medication contain one or more 
compounds with ototoxic properties (Table 1.3). Although there is no tool available to 
objectively measure the intensity or severity, questionnaires are available to help 
substantiate the effect of tinnitus on individuals‘ physical, emotional, social and 
occupational functioning (Newman, Jacobson, & Spitzer, 1996). 
Table 1.3: Medications and substances that can cause tinnitus (Crummer & Hassan, 
2004) 
Analgesics 
Aspirin 
Nonsteroidal anti-inflammatory drugs 
Antibiotics 
Aminoglycosides 
Chloramphenicol (Chloromycetin) 
Erythomycin 
Tetracycline 
Vancomycin (Vancocin) 
Chemotherapeutics 
Bleomycin (Blenoxane) 
Cisplatin (Platinol) 
Mechlorethamine (Mustargen) 
Methotrexate (Rheumatrex) 
Vincristine (Oncovin) 
Loop diuretics 
Bumetanide (Bumex) 
Ethacrynic (Edecrin) 
Furosemide (Lasix) 
Other 
Chloroquine (Aralen) 
Heavy metals: mercury, lead 
Heterocyclic antidepressants 
Quinine 
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1.6 Presbycusis 
In cases where a number of years have elapsed between the initial baseline assessment 
and any follow-up assessments, consideration should be given to the effect of age on 
hearing thresholds. Presbycusis is a general term that refers to hearing loss commonly 
associated with advancing age (Baloh, 1998) and is the result of a culmination of a 
lifetime of insults to the auditory system (Gates & Mills, 2005). Age-related hearing 
impairment is the most common sensory impairment in the elderly (Van Eyken, Van 
Camp, & Van Laer, 2007). Although the entire auditory system experiences changes with 
age, it appears that age-related structural changes to the external and middle ear do not 
typically have an adverse effect on audiometric function or speech understanding ability. 
In contrast, the cochlea undergoes significant changes as a result of the ageing process 
(Liu & Yan, 2007). Based on histological temporal bone examinations, presbycusis has 
been classified into six different types dependent on the main structures affected: sensory 
(loss of hair cells and supporting cells), neural (loss of ganglion cells), metabolic (atrophy 
of the stria vascularis), cochlear presbycusis (thickening of the basilar membrane), mixed, 
and indeterminate (Gates & Mills, 2005; Jordan & Roland, 2000). Mixed presbycusis is 
characterised by the presence of two or more of the classic types; while indeterminate, a 
relatively new classification, is characterised by submicroscopic alterations in the cochlea 
(Weinstein, 2002), and is reported to account for 25% of cases (Schuknecht & Gacek, 
1993). Despite these histological-based classifications, it is important to recognise that 
causation is complex and most likely multifactorial. For example, it is likely that genetic 
variance as well as a history of significant noise exposure contribute to the pathogenesis 
of presbycusis (Fuchs, 2010). 
The characteristic loss of high-frequency threshold sensitivity is generally thought of as 
the first sign of presbycusis, however, each classification has been associated with 
individual audiometric patterns. Sensory presbycusis is characterised by normal low-
frequency hearing with a steeply sloping high-frequency loss, often with a dip in the 4 kHz 
region resembling noise-induced hearing loss (Demeester et al., 2009; Liu & Yan, 2007). 
As hair cell loss occurs at the extreme basal end of the cochlea, the patient is likely to have 
good speech discrimination until the lower speech frequencies are affected (Weinstein, 
2002). Metabolic presbycusis has an audiogram characterised by a flat or slightly sloping 
configuration of mild to moderate severity (Demeester, et al., 2009) with good 
preservation of speech discrimination (Jordan & Roland, 2000). Cochlear presbycusis is 
assumed when other types of presbycusis are histologically excluded, and typically results 
in small decrements of high-frequency hearing (Weinstein, 2002), while neural 
presbycusis is not associated with any particular audiometric pattern (Demeester, et al., 
2009). 
The process of presbycusis can begin as early as young adulthood, but usually does not 
become evident until the fifth decade of life (Veras & Mattos, 2007).The prevalence of 
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presbycusis is generally thought to increase with advancing age and it is rare to find a 
person over the age of 70 who has not experienced a decline in hearing. A longitudinal 
study by Lee, Matthews, Dubno and Mills (2005) showed that on average hearing 
thresholds deteriorate approximately 1 dB per year for persons aged 60 years and over, 
depending on age, gender and initial thresholds. Variations are most evident in older 
adults at higher frequencies (Figure 1.10). 
 
Figure 1.10: Median hearing thresholds in decibel hearing level (dB HL) across 
frequencies 125 to 8000 Hertz (Hz) according to the ISO 7029 standards for males (left) 
and for females (right) aged 20 to 80 years in 10 year increments (Van Eyken et al., 
2006). 
1.7 Rationale for the current study 
Ototoxicity resulting from cisplatin chemotherapy constitutes a significant clinical 
problem that is currently tolerated as a side-effect of cancer treatment. At present there is 
no approved method for protecting or remedying against deterioration of hearing status. 
Therefore, the detection and appropriate management of cisplatin-induced ototoxicity is 
reliant on effective audiological monitoring. Guidelines for ototoxicity monitoring are not 
included in the Standards of Practice outlined by the governing body for audiologists in 
New Zealand, the New Zealand Audiological Society (NZAS). As a result, there is no 
cohesion, with protocols falling under the responsibility of individual audiology 
departments and clinics. 
1.8 Aims of the current study 
The present study has two main aims: 
1. The first aim is to investigate the prevalence of ototoxicity in head and neck 
oncology patients who received cisplatin in combination with cranial irradiation. 
2. The second aim of this study is to examine the current state of audiological 
monitoring for this population at Christchurch Hospital. 
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Guidelines established by ASHA emphasise the importance of pre-treatment assessment 
to provide a baseline measure for each individual patient. This is to be followed up with 
serial audiological assessments to monitor any deterioration in hearing status so that 
intervention and management can be timely and effective. This study will assess 
audiological monitoring via analysis of past audiometric data for the participants 
recruited into this study. Findings from this study will be useful in representing the 
current standard of audiological monitoring at Christchurch Hospital for patients 
receiving cochleotoxic therapy and how this may be improved. This is of particular 
relevance as this study precedes a Phase III clinical trial due to begin shortly at 
Christchurch Hospital, which proposes the trial of intratympanic dexamethasone 
administration to investigate potential protective effects against ototoxicity while 
preserving cisplatin‘s chemotherapeutic actions. 
This study aims to increase audiologist‘s awareness of ototoxicity and the importance of 
comprehensive audiological monitoring. This research has the potential to improve 
patient hearing care and consequently improve their quality of life. 
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2 Method 
2.1 Participants 
In the three-month period from January to March 2010, a total of 23 participants 
underwent diagnostic audiological assessment at Christchurch Public Hospital for the 
purpose of the present study. 
Individuals were eligible to be recruited into the present study based on the following 
criteria: 
 Aged 18 years or older 
 Previously received a diagnosis of carcinoma of the head and neck region 
 Received treatment with cranial irradiation and concurrent cisplatin chemotherapy 
for the treatment or management of their cancer. This subset of patients is 
considered to be at high risk of ototoxicity due to concurrent cisplatin therapy and 
cranial irradiation (Low, et al., 2006) 
 Canterbury District Health Board as their health provider 
Accordingly, 39 eligible individuals were identified via the Christchurch Hospital 
Oncology Pharmacy database and sent a letter in December 2009 outlining the study and 
inviting them to take part (Appendix B). No monetary incentive was offered. Initially, 24 
individuals accepted the invitation, giving a response rate of 61.5%. Unfortunately three 
individuals were not able to participate in the research; one individual was unable to be 
contacted via the contact details provided on the response form, one individual lived out 
of Christchurch and would not be available for testing until late 2010, and the last 
individual required an interpreter and was unable to be contacted to organise this. A 
follow-up letter was sent in February 2010 to the remaining 13 individuals who had not 
replied (Appendix C) in an attempt to increase participant numbers. Following this, an 
additional two individuals agreed to take part in this research giving an overall response 
rate of 66.7%. This is above the average response rate of 61% for postal correspondence 
and surveys (de Vaus, 2002). In total, 23 individuals were recruited for the present 
research. 
The demographic characteristics of the participants are shown in Table 2.1. The age of the 
patients ranged from 51 to 81 years with a mean age of 60.2 years, and included 21 males 
and two females. Of the 23 patients, 13 had been diagnosed with SCC of the oropharynx, 
three of the oral cavity, two of the hypopharynx, two of the larynx, one of the 
nasopharynx, one of the neck, and the diagnosis of one individual was unknown. A 
schematic diagram of the head and neck region is shown in Figure 2.1. 
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Figure 2.1: Diagram illustrating the different regions of the head and neck, including the 
oral cavity, nasopharynx, oropharynx, hypopharynx and larynx (American Cancer Society 
Inc, 2009). 
The malignancies were staged according to the tumour-node-metastasis (TNM) staging 
system of the American Joint Committee on Cancer (AJCC) and International Union 
Against Cancer (UICC) (Patel & Shah, 2005). The TNM system describes three key pieces 
of information: the size of the primary tumour (T), the extent of spread to nearby lymph 
nodes (N), and whether the cancer has metastasized to other organs of the body (M). 
Categories marked with an ‗X‘ indicate the primary tumour cannot be assessed, while ‗0‘ 
indicates no evidence of primary tumour. Grading 1 – 4, ‗a‘ and ‗b‘ indicate increasing 
severity and spread, respectively. 
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Table 2.1: Participant demographic characteristics, diagnosis, treatment dose, concurrent medications and comorbidities. 
Case 
Age 
(years) 
Sex Diagnosis 
TNM Staging 
criteria* 
Cisplatin dose (mg) Total 
cisplatin dose 
(mg) 
Total irradiation 
dose 
(Gy/Fractions) 
Concurrent 
medications 
Comorbidity 
Dose 1 Dose 2 Dose 3 
1 63 M Oral cavity T4N2bM0 190 190 190 570 70/35   
2** 59 M Oropharynx T2N2bMx 200 200  400 70/35 80 mg F NH Lymphoma 
3 57 M Unknown T0N2a 180 144 144 468 70/35   
4 56 M Nasopharynx T2N2c 200 200 200 600 70/35   
5 61 M Hypopharynx T2N2bMx 180 130  310 70/35  Renal dysfunction 
6 53 M Neck T0N2b 200 200 200 600 70/35   
7 55 M Larynx cT3N0 192 192 192 576 70/35  Atrial fibrillation 
8 52 M Oral cavity T4N2cM0 190 190 190 570 60/30   
9 69 M Larynx T4N1 200 200 200 600 70/35   
10*** 67 M Oropharynx T3N2bMx 200 200  400 70/35 20 mg F 
Hypertension, 
IDDM, Gout 
11 51 M Oral cavity T3N2cM0 190 190  380 60/30   
12 56 M Oropharynx pT3N1M0 190 190  380 60/30 40 mg F  
13 67 M Oropharynx cT3N2bM0 188 188 150 526 70/35   
14 55 M Oropharynx T3N2cM0 197 197  394 70/35  Hypertension 
15 57 M Oropharynx T1N2a 188   188 60/30   
16 63 M Oropharynx T1N2aM0 170 170 170 510 70/35   
17 71 F Oropharynx T3N2b 160   160 70/35  
Hypertension, 
Stroke 
18 81 F Hypopharynx T3N0 58 58 40 156 70/35   
19 68 M Oropharynx T2N2bM0 200 200 130 530 70/35  
Hypertension, 
Cardiomyopathy 
20 58 M Oropharynx T2N2bM0 217 173  390 70/35  
Hypertension, 
Gout 
21 58 M Oropharynx T1N2a 219 219 219 219 70/35  Hypertension 
22 52 M Oropharynx T1N3M0 187   187 70/35   
23 55 M Oropharynx cT3N2bM0 200 200  400 74/37  
Hep C, Renal & 
liver dysfunction 
 
* TNM staging criteria: refers to the size of the primary tumour (T), the extent of spread to nearby lymph nodes (N), and whether the cancer has metastasized to other 
organs of the body (M). ‗X‘ indicates the primary tumour cannot be assessed, ‗0‘ indicates no evidence of primary tumour‘, while grading 1 – 4, ‗a‘ and ‗b‘ indicate 
increasing severity and spread, respectively. 
** Patient received R-CHOP chemotherapy for Non-Hodgkin‘s Lymphoma in June 2008. 
*** Patient had previous history of metastatic melanoma in 1983 requiring radical neck dissection. 
Abbreviations: F, frusemide; NH, non-hodgkins; IDDM, insulin dependent diabetes mellitus 
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2.1.1 Treatment protocol 
Patients were prescribed cranial irradiation therapy with concurrent cisplatin 
chemotherapy. Surgery was also employed where necessary. 18 patients received 
irradiation of 70 Gy in 35 fractions, four received a lower dose of 60 Gy in 30 fractions, 
and one received a dose of 74 Gy in 35 fractions. Cisplatin was typically charted for days 1, 
22 and 43. Patients were required to be admitted overnight to allow for sufficient 
hydration. Cisplatin was administrated IV in 1000 ml of 0.9 saline at a rate of 1 mg 
cisplatin per minute. In conjunction, patients were given the following: 
 1000 ml 0.9 saline over one hour; 
 Dexamethasone 16 mg in 1000 ml over one hour; 
 1000 ml 0.9 saline with 100 ml 15% Mannitol (osmotic diuretic) over one hour; 
 1000 ml 0.9 saline with 100 ml 15% Mannitol over four hours; 
 1000 ml 0.9 saline with 30 mmol KCL over six hours; 
 1000 ml 0.9 saline with 30 mmol KCL over six hours; 
 three 8 mg doses of the anti-emetic Ondansetron were administered at 12 hour 
intervals. 
The total cisplatin dose ranged from 188 mg to 657 mg with a mean dose of 413.6 mg. No 
other chemotherapy agents were administered. 
2.2 Procedure 
The protocol used in this study is described below. This protocol was based on previous 
findings in the literature with consideration to the equipment that was available for use. 
Invitation letters were sent out to the 39 eligible individuals along with a response form 
and a preaddressed and stamped envelope. Individuals also had the option of contacting 
the author via email or phone as listed on the invitation letter. All 23 participants were 
contacted via their preferred communication mode as stated on their response form to 
arrange an appropriate appointment time. Prior to the assessments, a hand search of the 
Christchurch Audiology and Ear, Nose and Throat (ENT) Department oncology 
audiogram files was undertaken to match any previous audiograms to participating 
individuals. 
At the appointment, all participants underwent diagnostic audiological assessment 
involving a case history, otoscopy, tympanometry, ipsilateral acoustic reflexes, standard 
pure-tone audiometry (0.25 to 8 kHz) and extended high frequency audiometry (9 to 16 
kHz), speech audiometry, and distortion product otoacoustic emissions (DPOAEs). All 
testing was carried out in sound treated rooms in the Audiology Department at 
Christchurch Public Hospital. To ensure consistency, all testing was performed by the 
author. A more detailed outline of all procedures is presented below. 
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2.2.1 Pure-tone audiometry 
Pure-tone thresholds in dB HL were ascertained using the modified Hughson-Westlake 
method (Carhart & Jerger, 1959). A calibrated Grason-Stadler GSI 61 Clinical Audiometer 
was used to generate pure tones that were presented to each ear via Etymotic Research 
ER-3A insert earphones for standard pure-tone audiometry, Sennheiser HDA 200 
circum-aural headphones for extended high-frequency audiometry, and a Radioear B-71 
bone conductor. In cases where insert earphones were contra-indicated, Telephonics 
TDH-59P headphones were used. Each participant‘s air conduction thresholds were 
measured in 5 dB steps at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 9, 11.2, 12.5, 14 and 16 kHz in each ear. 
Bone conduction thresholds were measured from 0.5 – 4 kHz only, where air conduction 
thresholds were 20 dB HL or greater at the relevant frequency(s). Threshold was defined 
as the lowest intensity at which two reliable ascending responses were obtained. Pulsed 
tones were used as they are perceived as being easier to distinguish without adversely 
affecting the results (Burk & Wiley, 2004; Hamill & Haas, 1986), particularly for tinnitus 
sufferers (Mineau & Schlauch, 1997). Air conduction masking using a plateau method was 
applied to establish true audiometric thresholds when the air conduction thresholds of 
the test ear and of the non-test ear differed by at least the minimum inter-aural 
attenuation value for the test frequency. Specifically, the following values were used; 75 
dB HL at 0.5 and 1 kHz, and 50 dB HL at frequencies above 1 kHz, where ER-3A 
earphones were used; 40 dB HL at 0.5 and 1 kHz, 45 dB HL at 2 kHz, and 50 dB HL at 4 
kHz, where TDH-59P headphones were used. Bone conduction masking using the plateau 
method was also applied when there was an air-bone gap present equal to or greater than 
15 dB HL. 
2.2.2 Speech audiometry 
Speech audiometry was performed using the New Zealand Recording of CVC (Revised 
AB) Word Lists (National Audiology Centre, Auckland, New Zealand). The word lists were 
presented using portable compact disc (CD) players (Sony D-EJ011 and Aistar ESP 
A5252) and a calibrated Grason-Stadler GSI 61 Clinical Audiometer, via ER-3A insert 
earphones or TDH-59P headphones. The maximum word recognition score was 
ascertained by recording the percentage of phonemes correctly repeated when the stimuli 
were presented 30 dB above the participant‘s pure-tone threshold average (PTA) of 0.5, 1 
and 2 kHz where the hearing loss was relatively flat, or the two best thresholds at these 
frequencies if the audiogram was steeply sloping. If the maximum word recognition score 
was less than 90%, presentation of the stimuli was increased by 10 dB. The speech 
reception threshold (SRT), defined as the lowest intensity at which 50% of the phonemes 
can be correctly discriminated, was determined from a performance intensity (PI) 
function ascertained in 10 – 15 dB steps. Speech masking was applied to the contralateral 
ear when the presentation level of the speech stimuli exceeded the best bone conduction 
threshold of the non-test ear by the appropriate interaural attenuation value, depending 
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on the type of transducer used. Specifically, 55 dB HL where ER-3A earphones were used, 
and 45 dB HL where TDH-59P headphones were used. 
2.2.3 Immittance audiometry 
2.2.3.1 Tympanometry 
Tympanometry was performed using a Grason-Stadler TympStar Middle-Ear Analyzer. A 
stimulus tone of 226 Hz was used, with a sweep rate of 50 daPa per second. The traces 
were compared to norms published by (American Speech-Language-Hearing Association, 
1990) to determine tympanogram type. Type A tympanograms, consistent with normal 
middle ear pressure and compliance, were defined by ear canal volume of 0.6 – 1.5 cm³, 
peak pressure between −100 and +100 daPa, and static admittance between 0.3 – 1.4 
mmho. Traces with normal ear canal volume and peak pressure, but deviations in static 
admittance either above or below the normal range, were classified as Type Ad and Type 
As respectively. Traces with peak pressure less than −100 daPa were classed as Type C 
tympanograms, consistent with eustachian tube dysfunction and resulting in a retracted 
tympanic membrane. Where ear canal volume was normal and no peak pressure 
identified, traces were classed as Type B tympanograms, consistent with middle ear 
dysfunction. A Type B tympanogram with lower than normal ear canal volume was 
classed as a Type B-low, suggestive of wax occlusion or positioning of the probe tip 
against the EAC wall. A Type B tympanogram with higher than normal ear canal volume 
was classed as a Type B-high, consistent with tympanic membrane perforation or patent 
ventilation tube. 
2.2.3.2 Acoustic reflexes 
Ipsilateral acoustic reflexes (AR) were carried out using a Grason-Stadler TympStar 
Middle-Ear Analyzer. Stimuli were initially presented at 80 dBSPL, increasing in 5 dB 
steps until a significant compliance change was noted, equal or greater than o.02 mmho. 
The stimulus was increased a further 5 or 10 dB to check for growth of the response. The 
acoustic reflex threshold (ART) was defined as the lowest intensity at which two reliable 
responses were obtained. ARTs were sought at 0.5, 1, 2 and 4 kHz bilaterally. 
2.2.4 Distortion product otoacoustic emissions measurement 
DPOAEs were evoked and recorded using a Grason-Stadler GSI 60 DPOAE System. The 
stimuli consisted of two primary pure-tones, f1 and f2, with an intensity level fixed at 65 
dB SPL (L1) and 55 dB SPL (L2), respectively, and with a frequency ratio (f2/f1) of 1.22. An 
f1/f2 ratio of 1.22 has been shown to generate maximal distortion across all frequencies 
and subjects (Gaskill & Brown, 1990). The amplitude is also affected by the overall level 
and the level difference between the two primary tone levels (L1 – L2). High-intensity 
primaries elicit high amplitude DPOAEs but are thought to reflect passive cochlear 
processes as demonstrated by DPOAEs recorded from dead or damaged cochleae (Zurek, 
Clark, & Kim, 1982). It has been suggested that moderate level primaries, L1 = 65 dB SPL 
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and L2 = 55 dB SPL, are preferable for clinical use due to increased accuracy in 
distinguishing between normal and hearing impaired ears (Stover, Gorga, Neely, & 
Montoya, 1996). 
The testing was performed for 16 ascending frequencies where f2 varied from 2.0 to 9.25 
kHz. DPOAE amplitude and noise floor were displayed for each frequency as DP-grams. 
An emission was considered present if the SNR was greater than 6 dB and the absolute 
amplitude greater than -10 dB SPL (Hall, 2000). 
2.3 Statistical methods 
All data were entered and analysed using Microsoft Excel 2007. The primary methods for 
analysis were measures of central tendency and measures of variability. Level of hearing 
was calculated as the PTA of 0.5, 1, 2, and 4 kHz for standard audiometry, and the PTA of 
9, 10, 11.2 and 12.5 kHz for EHF audiometry. When determining whether a significant 
cochleotoxic change had occurred (American Speech-Language-Hearing Association, 
1994), individual thresholds were analysed at each frequency. A Fisher‘s exact test was 
undertaken to investigate whether participants were able to accurately perceive a 
significant cochleotoxic change in their hearing. The Fisher‘s exact test was used due to 
the expected count of some cells being less than 5. 
Due to the small sample size, many statistical tests were not appropriate. In addition, the 
focus of this study was to determine the clinical significance of the findings. For example, 
although a change in hearing thresholds may constitute a statistically significant result, if 
it falls within the ± 10 dB test-retest reliability it will have little relevance to the clinical 
management of the patient. 
2.4 Ethical considerations 
Ethical approval from the Upper South B Regional Ethics Committee was granted on 2 
November 2009 (Ref: URB/09/41/EXP, see Appendix A). Written consent was obtained 
from each participant prior to audiological assessment (Appendix E), and patient 
confidentiality was maintained in accordance with the conditions of ethical approval from 
the above-named ethics committee. 
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3 Results 
The results of this study will be reported in several sections. First, details of pre-treatment 
assessments obtained from patient files will be presented, followed by the audiometric 
data collected from the post-treatment assessments carried out by the author. The last 
section pertains to analysis of data with respect to the cochleotoxicity criteria stipulated 
by ASHA. This includes four case studies that were of particular interest. 
3.1 Pre-treatment audiological assessment 
From the total sample of 23 participants who were recruited for this study, 16 (69.6%) 
individuals had undergone pre-treatment audiological assessments. This is displayed in 
Figure 3.1. These assessments consisted of standard pure-tone audiometry for all 16 
(100%) participants, and EHF audiometry for 14 (87.5%) participants. 
The pre-treatment standard PTA of 0.5, 1, 2 and 4 kHz for both ears was calculated for 
each of these 16 individuals. The mean pre-treatment standard PTA across all 16 
participants was 20.9 ± 11.3 dB HL for the left ear, and 20.9 ± 9.3 dB HL for the right ear. 
The mean PTA for both ears was 20.9 ± 10.2 dB HL. The extended high-frequency pure-
tone average (EHF PTA) of 9, 10, 11.2 and 12.5 kHz was calculated for each individual. In 
cases where there was no response at the limit of the audiometer for a particular 
frequency, the PTA is reported as being at least the specified value. This signifies that the 
reported PTA is most likely an underestimation of the true PTA. The mean pre-treatment 
EHF PTA across all 16 participants was at least 50.7 ± 15.5 dB HL for the left ear, and at 
least 50.6 ± 14.5 dB HL for the right ear. The mean EHF PTA for both ears was at least 
50.7 ± 14.7 dB HL. Mean pre-treatment pure-tone audiometry results are displayed in  
Figure 3.2 and Figure 3.3. 
 
Figure 3.1: Proportion of participants who had undergone pre-treatment assessment (16 
of 23 participants, or 69%). 
Pre-treatment assessment No assessment
42 
 
Figure 3.2: Mean e-treatment pure-tone air conduction thresholds in decibel hearing level 
(dB HL) in the right ear for 16 participants. 
 
 
Figure 3.3: Mean pre-treatment pure-tone air conduction thresholds in decibel hearing 
level (dB HL) in the left ear for 16 participants. 
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Tympanometry was performed on 15 (93.8%) participants in total, with bilateral 
measurements for 14 (87.5%) participants and unilateral (right ear only) for one (6.3%) 
participant (participant 13). Of those 15 participants, ten (66.7%) participants had type 
―A‖ tympanograms bilaterally, indicating normal middle ear pressure and compliance. 
Participant 13 had a type ―A‖ tympanogram in his right ear. One (6.7%) participant had 
type ―C‖ tympanograms bilaterally, consistent with Eustachian tube dysfunction resulting 
in retracted tympanic membranes. One (6.7%) participant had a unilateral type ―C‖ 
tympanogram. One (6.7%) participant had bilateral type ―Ad‖ tympanograms while two 
(13.3%) participants had unilateral type ―Ad‖ tympanograms, consistent with greater than 
normal compliance. 
Ipsilateral ARs were performed bilaterally on one (6.3%) participant. Pre-treatment 
speech audiometry and DPOAEs were not performed on any of the 16 participants. Table 
3.1 provides pre-treatment assessment details for each participant. 
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Table 3.1: Pre-treatment audiological assessment information for each of the 16 participants. 
Participant 
Age 
(years;months)* 
Gender 
Pure-tone average 
(dB HL)** 
EHF Pure-tone average 
(dB HL) *** 
Tympanogram type Acoustic 
reflexes 
Left ear Right ear Left ear Right ear Left ear Right ear 
1 62;5 Male 11.3 13.8 53.8 53.8 A A  
4 54;2 Male 22.5 40   C C  
5 60;6 Male 7.5 6.3 56.3 42.5 A A  
6 51;9 Male 28.8 20 63.8 56.3 Ad Ad  
7 52;7 Male 13.8 13.8 32.5 28.8 A A  
8 51;2 Male 23.8 20 52.5 51.3 A A  
9 66;2 Male 27.5 16.3 91.3 83.8 C Ad  
11 50;9 Male 31.3 32.5 47.5 42.5 A A X 
12 52;2 Male 11.3 12.5 31.3 47.5 A A  
13 64;0 Male 27.5 28.8 36.3 41.3  A  
14 53;9 Male 23.8 25 53.8 41.3    
17 67;9 Female 51.3 35   A A  
19 67;9 Male 16.3 21.3 55 53.8 A A  
21 56;6 Male 7.5 11.3 56.3 58.3 A A  
22 48;9 Male 20 20 45 72.5 A Ad  
23 52;9 Male 11.3 17.5 35 35 A A  
 
* Age at time of pre-treatment assessment 
** Pure-tone average of 0.5, 1, 2 and 4 kHz 
*** Pure-tone average of 9, 10, 11.2 and 12.5 kHz 
EHF - extended high-frequency 
N.B. Values in italics represent pure-tone averages where one or more of the component frequencies yielded a threshold that was considered to be no response at the limit of 
the audiometer.
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3.2 Post-treatment audiological assessment 
All 23 participants underwent post-treatment audiological assessments performed by the 
author. These involved case history, standard and EHF pure-tone audiometry, speech 
audiometry, DPOAEs and immittance audiometry. Information pertaining to the research 
aims is presented below. Comprehensive assessment details of each participant can be 
found in Appendix F. 
3.2.1 Case history 
3.2.1.1 Hearing loss 
At the time of the post-treatment assessment, 20 (87%) participants out of the total 
sample (n = 23) felt that they had hearing loss in either one (10%) or both ears (90%). Of 
those 20 participants, nine participants (45%) believed that they had hearing loss pre-
treatment but that their hearing had deteriorated further since receiving treatment for 
cancer, six (30%) participants reported that their hearing loss had come on as a result of 
treatment, while the remaining five (25%) participants felt that their hearing had not 
changed after treatment. Overall, 15 (65%) of the 23 participants reported hearing loss 
that they believed to be a direct result of their cancer treatment. The mean length of 
hearing loss was 10.47 ± 16.70 years. Of those 15 participants, 10 (66.7%) described the 
onset of their hearing loss as ―gradual‖, four (26.7%) described it as ―sudden‖ onset, while 
the remaining one (6.7%) participant was unsure. Of the 15 participants, 14 (93.3%) felt 
that the hearing loss they experienced affected both ears and one (6.7%) participant felt 
that it affected the right ear only. 
Participants were asked what environments, if any, they experienced difficulty hearing in. 
Of the 20 participants who reported hearing loss, 19 (95%) said that noisy environments 
were difficult, 17 (85%) found group conversations a problem, 16 (80%) found they 
required the television or radio volume turned up, eight (40%) reported difficulty 
understanding speech when talking on the telephone, three (15%) participants 
experienced difficulty with conversations in quiet environments and when conversing 
with one other person. Of the 15 participants who reported hearing loss post-treatment, 
14 (93.3%) found noisy environments difficult, 13 (86.7%) said they experienced difficulty 
with group conversations and when listening to the television and/or radio, seven (46.7%) 
described conversations on the telephone difficult, and three (20%) participants reported 
problems with conversations in quiet environments and when conversing with one other 
person. 
3.2.1.2 Tinnitus 
During questioning, 18 participants (78.3%) reported experiencing tinnitus at some stage 
during their life. While eight (44.4%) of these 18 participants were not sure of the 
duration of their tinnitus, the mean length of time tinnitus was experienced by the other 
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ten (55.6%) participants was 5.98 ± 5.99 years. Of those 18 participants, five (27.8%) 
participants experienced tinnitus prior to their cancer treatment and felt that there had 
been no change; three (16.7%) participants experienced tinnitus prior to treatment but 
felt that it had increased in severity at the time of treatment; eight (44.4%) participants 
reported the onset of tinnitus coincided with their treatment, with one experiencing 
temporary tinnitus lasting eight to nine months only; one (5.6%) participant felt that their 
tinnitus had been affected by the treatment but was unsure whether it had started or 
increased in severity; and one (5.6%) participant was unsure whether their tinnitus had 
been affected by the treatment. Of the total sample, 11 (47.8%) participants felt that their 
tinnitus had either begun or increased in severity as a result of treatment. Participant 15 
received only one dose of cisplatin due to a significant increase in tinnitus severity. 
Participants were asked to choose the best description of what their tinnitus sounded like; 
of the 18 participants who reported either a history of, or current tinnitus, seven (38,9%) 
described a ―ringing‖ sound, three (16.7%) described a ―buzzing‖ sound, two (11.1%) 
described a ―hissing‖ sound, one (5.6%) described a sound like ―crickets‖, and one (5.6%) 
described a ―whistle‖ sound. Four (22.2%) participants chose the ―other‖ description and 
included ―zinging‖, ―squeal‖ and ―sea noise/waves‖. Participant six did not answer this 
question as he did not currently have tinnitus and was unable to remember what it 
sounded like. 
3.2.1.3 Balance 
Seven (30.4%) participants reported difficulties with their balance. Of these seven 
participants, two (28.6%) described problems relating to low blood pressure, one (14.3%) 
reported a history of benign paroxysmal positional vertigo (BPPV), while the remaining 
four (57.1%) described a feeling of imbalance that was noticed since receiving treatment. 
3.2.1.4 Aural fullness 
Seven (30.4%) participants described a feeling of aural fullness or pressure in one or both 
ears. Four participants reported the onset of these symptoms with treatment. 
3.2.1.5 Facial weakness 
Twelve (52.2%) participants reported facial numbness or weakness. All 12 (100%) 
participants believed this occurred as a direct result of surgery to remove either the 
tumour and/or affected lymph nodes. 
3.2.1.6 Noise exposure 
Twenty-one (91%) participants out of 23 reported exposure to significant noise either 
through their occupation or recreational activities. The mean length of exposure was 
22.05 ± 12.91 years. Of these 21 participants, 9 (42.6%) participants reported wearing 
some form of hearing protection at least some of the time, while the remaining 12 (57.1%) 
did not wear hearing protection. 
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The percentage of participants who reported the three main ototoxic symptoms are 
presented in Figure 3.4 while case history information for each participant is detailed in 
Table 3.2. 
 
Figure 3.4: Percentage of participants who reported experiencing each symptom post-
treatment (n=23). 
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Table 3.2: Case history information for each of the 23 participants. HL: hearing loss, Tx: treatment, Y: yes, N: no, NS: not sure, Q: quiet, NE: noisy, G: groups, P: phone, TV/R: TV/radio  
Patient HL 
HL from 
Tx 
Onset of 
HL 
Ear 
Problem 
situations 
Tinnitus 
Tinnitus 
from Tx 
Tinnitus 
sound 
Balance 
Aural 
fullness 
Facial 
numbness 
Ear 
surgery 
Noise 
exposure 
1 Y N Gradual Both NE, G, TV/R Y N Ringing N N Y N Y 
2 Y Y Gradual Both NE, G, P, TV/R Y Increased Crickets N N N N Y 
3 Y Y Sudden Both NE, G, P, TV/R Y N Buzzing N N N N Y 
4 Y Y Sudden Both Q, G, P Y N Hissing N N N N Y 
5 Y Y Gradual Both NE, G, TV/R Y NS Ringing N N N N Y 
6 Y N Gradual Both TV/R Y N  Y N Y N Y 
7 Y Y Sudden Both NE, G, TV/R Y Increased Whistle N Y Y N Y 
8 NS N Gradual Left NE, G N   N N Y N Y 
9 Y Y NS Both NE, P, TV/R Y Onset Ringing N Y N N Y 
10 Y Y Gradual Both Q, NE, T, G, TV/R N   N N Y N Y 
11 N N   TV/R N   N Y Y N N 
12 Y N Gradual Both NE, G, P Y N Ringing Y N Y N Y 
13 Y Y Gradual Both Q, NE, G, TV/R Y Increased Buzzing N N N N Y 
14 Y Y Gradual Both NE, G, P, TV/R Y Onset Zinging N N N N Y 
15 Y N Sudden Both NE Y Onset Squeal Y N Y N Y 
16 N N    Y Onset Hissing N N N N N 
17 Y Y Gradual Both NE, T, G N   N N Y N Y 
18 Y Y Gradual Both NE, P, TV/R N   Y Y Y N Y 
19 Y N Gradual Both NE, G Y Onset Ringing N Y N N Y 
20 Y Y Gradual Right NE, G, P, TV/R Y Onset Squeal Y N Y N Y 
21 Y Y Gradual Both NE, G, TV/R Y Y Waves Y Y Y N Y 
22 Y Y Sudden Both NE, G, TV/R Y Onset Ringing N N N N Y 
23 Y Y Gradual Both NE, T, G, TV/R Y* Onset Ring,Buzz Y Y N N Y 
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3.2.2 Pure-tone audiometry 
For this section please note that a threshold shift is considered clinically significant when 
there is a difference of 15 dB or greater between tests. This allows for ± 5 dB test-retest 
reliability. Fluctuations of thresholds between tests of 10 dB or less have therefore not 
been reported. In addition, the classification used when describing degree of hearing loss 
is that of Jerger and Jerger (1980) which states the following:  
-10 to 20 dB HL  Normal hearing 
21 to 40 dB HL  Mild hearing loss 
41 to 55 dB HL  Moderate hearing loss 
56 to 70 dB HL  Moderately-severe hearing loss 
71 to 90 dB HL  Severe hearing loss 
91+ dB HL  Profound hearing loss 
The pure-tone threshold average (PTA) of 0.5, 1, 2 and 4 kHz for both ears was calculated 
for each of the 23 individuals. The mean PTA of the total sample was 31.8 ± 13.8 dB HL 
for the left ear, and 29.2 ± 9.7 dB HL for the right ear. The mean PTA for both ears was 
30.5 ± 11.9 dB HL. The extended high-frequency pure-tone average (EHF PTA) of 9, 10, 
11.2 and 12.5 kHz was calculated for each individual. The mean EHF PTA of the total 
sample was 70.9 ± 13.7 dB HL for the left ear, and 71.7 ± 12.6 dB HL for the right ear. The 
mean EHF PTA for both ears was 71.3 ± 13.0 dB HL. Post-treatment pure-tone 
audiometry results are displayed in Figure 3.5 and Figure 3.6. 
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Figure 3.5: Post-treatment pure-tone air conduction thresholds in the right ear for all 23 
participants 
 
 
Figure 3.6: Post-treatment pure-tone air conduction thresholds in the left ear for all 23 
participants 
3.2.3 Speech audiometry 
Speech audiometry was performed for all 23 participants and was consistent with the 
pure-tone audiogram (see Appendix F). 
3.2.4 DPOAEs 
DPOAEs were performed on 18 participants (78.3%). The remaining five participants 
were not assessed due to time constraints (participants 9, 10 and 23), unwillingness of the 
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(participant 7). Participant 15 was assessed using another brand of equipment (Audera) 
that measured emissions at different frequencies to the GSI 60. Interpolation did not 
accurately represent OAE results and therefore the data collected from participant 15 are 
not included in the analysis. DPOAE data are displayed for each participant in Table 3.3. 
3.2.5 Immittance audiometry 
3.2.5.1 Tympanometry 
Tympanometry was performed on 21 (91.3%) participants in total, with bilateral 
measurements for 19 (82.6%) participants and unilateral for two (8.7%) participants 
(participants 13 and 15). Of those 21 participants, 15 (71.4%) participants had type ―A‖ 
tympanograms bilaterally, consistent with normal middle ear pressure and compliance. 
One (4.8%) participant (participant 13) had a type ―A‖ tympanogram in his right ear. Type 
―Ad‖ tympanograms, consistent with greater than normal compliance, were measured 
bilaterally in one (4.8%) participant, and unilaterally in two (9.5%) participants 
(including participant 15). One (4.8%) participant had a unilateral type ―As‖ 
tympanogram, consistent with reduced compliance, while the remaining participant 
presented with a unilateral type ―C‖ tympanogram, consistent with Eustachian tube 
dysfunction resulting in retracted tympanic membranes. 
3.2.5.2 Acoustic reflexes 
Acoustic reflexes were measured for 14 (60.9%) participants in total, with bilateral 
measurements for 12 (85.7%) of those participants and unilateral measurements for the 
remaining two (14.3%) participants. ART values are displayed for each participant in 
Table 3.4. 
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Table 3.3: Distortion product otoacoustic emission (DPOAE) data from 18 participants. Hz: hertz, P: participant, L: left, R: right, : present(SNR > 5 dB, ≥ 10 
dB SPL) 
 Distortion product otoacoustic emission (DPOAE) F2 (Hz) 
P 2000 2250 2500 2750 3062 3375 3750 4062 4500 5000 5500 6125 6812 7500 8375 9250 
 L R L R L R L R L R L R L R L R L R L R L R L R L R L R L R L R 
1                                 
2                                 
3                                 
4                                 
5                                 
6                                 
8                                 
9                                 
11                                 
12                                 
13                                 
14                                 
16                                 
17                                 
20                                 
21                                 
22                                 
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Table 3.4: Ipsilateral acoustic reflex thresholds for right and left ears of 14 participants 
Participant Right ear Left ear 
 0.5 kHz 1 kHz 2 kHz 4 kHz 0.5 kHz 1 kHz 2 kHz 4 kHz 
1 85 85 95 100 85 85 95 100 
2 95 95 105 100     
3 105 105 105 100 100 105 105 100 
4 95 95 105 100     
7 95 85 90 100 80 80 80 95 
8 90 85 90 100 90 90 95 100 
9 105 105 105 100 110 110 105 100 
10 90 90 100 100 85 85 105 100 
11 80 80 80 80 80 80 80 80 
12 100 95 105 100 90 85 95 95 
14 85 90 85 100 95 95 95 100 
20 110 105 105 100 110 110 105 100 
21 90 85 85 100 90 85 85 100 
22 105 105 105 100 95 90 90 100 
 
 Denotes ―no response‖ either at the limit of the equipment or when the stimulus was 
too loud for the participant to tolerate. 
3.3 Serial audiological assessment 
Of the 16 participants who received a pre-treatment audiological assessment, 11 of them 
had at least one further assessment for the purposes of monitoring before the post-
treatment assessment for this study. Two additional participants, who had not had a pre-
treatment assessment, underwent audiological assessment during the treatment phase. 
Participant 15, who received only one dose of cisplatin due to a substantial increase in 
tinnitus severity, did not receive any form of audiological assessment prior to the post-
treatment assessment carried out for the purpose of this research. 
3.4 Cisplatin-induced hearing loss 
The baseline data from the 16 participants who underwent audiological assessment prior 
to beginning treatment, was compared with the data from the post-treatment assessment. 
In particular, results were analysed to see whether a cochleotoxic threshold shift had 
occurred based on the ASHA criteria of: (1) ≥ 20 dB decrease at any one test frequency; 
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(2) ≥ 10 dB decrease at any two adjacent test frequencies; or (3) loss of response at three 
consecutive test frequencies where responses were previously obtained. 
Overall, 15 (93.8%) of the 16 participants experienced a significant cochleotoxic change in 
thresholds. This was bilateral in 13 (86.7%) participants and unilateral in the remaining 2 
(13.3%). Thirteen (81.3%) of the 16 participants experienced a change in thresholds in 
their left and/or their right ear that met the first ASHA criterion, 15 (93.8%) of the 16 
participants experienced a change in their left and/or right ear that met the second ASHA 
criterion. Participants 5 and 21 experienced temporary shifts in thresholds that met the 
third ASHA criterion, but these had recovered by the final assessment. This is illustrated 
in Figure 3.7. Details for each of the 16 participants are displayed in Table 3.5. 
The survey data revealed that of the 16 participants who had a pre-treatment audiogram, 
10 participants had perceived deterioration in their hearing and had a measureable 
change (based on any of the three ASHA criteria), 5 participants had not perceived a 
deterioration in their hearing when there had in fact been a measureable change, and the 
remaining one participant had not perceived a change in hearing and had not had a 
measureable hearing loss. That is, all of the participants who perceived a loss of hearing 
actually had a measurable hearing loss. 
If the 15 participants who had suffered a measurable hearing loss were simply guessing 
whether they had a hearing loss, one would expect 50% to indicate that they had 
perceived a hearing loss and 50% to indicate that they had not perceived a hearing loss. 
Fisher‘s exact test (Fisher, 1922) shows that the probability of 10 or more participants 
correctly perceiving a hearing loss by chance is 15.1%, which is more than the commonly 
used 5% threshold. While the data are not conclusive, they do indicate that participants 
tend to perceive correctly when they have experienced a measurable deterioration in their 
hearing. 
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Figure 3.7: Number of participants (n=16) who experienced a significant long-term 
cochleotoxic deterioration in hearing thresholds based on the three ASHA criteria of (1) ≥ 
20 dB decrease at any one test frequency; (2) ≥ 10 dB decrease at any two adjacent test 
frequencies; or (3) loss of response at three consecutive test frequencies where responses 
were previously obtained
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Table 3.5: Standard and extended high-frequency pure-tone audiometry averages and ASHA cochleotoxicity criteria for each of the 16 participants 
Participant 
Pre-treatment assessment Post-treatment assessment ASHA cochleotoxicity criteria  
PTA (dB HL) 
EHF PTA 
(dB HL) 
PTA (dB HL) 
EHF PTA 
(dB HL) 
1 2 3 Any 
Left 
ear 
Right 
ear 
Left 
ear 
Right 
ear 
Left 
ear 
Right 
ear 
Left 
ear 
Right 
ear 
Left 
ear 
Right 
ear 
Left 
ear 
Right 
ear 
Left 
ear 
Right 
ear 
 
1 11.25 13.75 53.75 53.75 28.75 27.5 71.25 67.5 Yes Yes Yes Yes No No Both 
4 22.5 40   43.75 37.5 86.25 78.75 Yes No Yes No No No Left 
5 7.5 6.25 56.25 42.5 13.75 21.25 85 82.5 Yes Yes Yes Yes No No Both 
6 28.75 20 63.75 56.25 16.25 13.75 56.25 48.75 No No No No No No No 
7 13.75 13.75 32.5 28.75 26.25 21.25 71.25 66.25 Yes Yes Yes Yes No No Both 
8 23.75 20 52.5 51.25 27.5 25 62.5 62.5 Yes Yes Yes Yes No No Both 
9 27.5 16.25 91.25 83.75 53.75 23.75 86.25 90 Yes Yes Yes Yes No No Both 
11 31.25 32.5 47.5 42.5 32.5 37.5 63.75 61.25 Yes Yes Yes Yes No No Both 
12 11.25 12.5 31.25 47.5 10 16.25 42.5 52.5 No No Yes Yes No No Both 
13 27.5 28.75 36.25 41.25 30 33.75 55 60 Yes Yes Yes Yes No No Both 
14 23.75 25 53.75 41.25 30 30 60 63.75 Yes Yes Yes Yes No No Both 
17 51.25 35 DNT DNT 58.75 41.25 82.5 78.75 No Yes Yes Yes No No Both 
19 16.25 21.25 55 53.75 28.75 35 71.25 75 Yes Yes Yes Yes No No Both 
21 7.5 11.25 56.25 58.75 7.5 15 57.5 63.75 No No No Yes No No Right 
22 20 20 45 72.5 32.5 30 56.25 86.25 Yes Yes Yes Yes No No Both 
23 11.25 17.5 35 35 30 25 85 88.75 Yes Yes Yes Yes No No Both 
** Pure-tone average (PTA) of 0.5, 1, 2 and 4 kHz, *** Pure-tone average (PTA) of 9, 10, 11.2 and 12.5 kHz. EHF, extended high-frequency; DNT, did not test 
N.B. Values in italics represent pure-tone averages where one or more of the component frequencies yielded a threshold that was considered to be no response at the 
limit of the audiometer 
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3.4.1 Influencing variable 
For the 16 participants there was considerable variation in the duration between pre- and 
post-treatment assessments. Given the mean age of the participants (60.2 years), the 
deterioration in hearing thresholds within this time period may be partly attributed to 
other factors such as presbycusis. Thresholds were calculated using the NAL percentage 
binaural hearing handicap {Macrae, 1976 #191} and adjusted for age. The mean pre-
treatment percentage binaural hearing loss was 4.8 ± 4.4, and 4.0 ± 4.5 age corrected. 
The mean post-treatment percentage binaural hearing loss was 12.7 ± 8.8, and 11.3 ± 8.3 
age corrected. The mean percentage binaural hearing loss that occurred between the pre- 
and post-treatment assessments were 6.2 ± 4.7 and 5.7 ± 4.5 age corrected. Individual 
results for the 16 participants are displayed in Table 3.6. 
Table 3.6: Change in percentage binaural hearing loss adjusted for age and time elapsed 
between pre-and post-treatment assessments. Time in year;month. HL: hearing loss. 
Participant Time Pre-Treatment Post-Treatment Overall 
  % HL 
Age 
adjusted 
% HL 
Age 
adjusted 
Age 
adjusted 
1 1;3 0.7 -1 9 6.9 7.9 
4 2;8 8.3 8.3 18.9 18.9 10.6 
5 1;2 0 -1 2.7 1.3 2.3 
6 1;4 5.7 5.7 0.9 0.9 -4.8 
7 2;5 0.8 0.8 12.1 12.1 11.3 
8 0;11 3.2 3.0 7.2 7.2 4 
9 3;2 4.6 1.2 13.9 8.9 7.7 
11 0;7 9.9 9.9 16.4 16.4 6.5 
12 4;2 1.8 1.8 0.8 0. -1 
13 3;1 8.5 6 15.7 11.8 5.8 
14 1;7 6.9 6.9 13.1 13.1 6.2 
17 3;10 16 15.7 29.9 28.9 13.2 
19 0;11 6 2.1 14.2 9.8 7.7 
21 1;6 1.5 1.5 1.4 0.9 0.6 
22 4;1 2.9 2.9 9.8 9.8 6.9 
23 2;6 0.3 0.3 8.9 8.9 8.6 
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3.5 Case studies 
Two of the 15 participants who experienced a significant cochleotoxic threshold shift were 
noted to have acute renal failure that prevented them from receiving the third dose of 
cisplatin. One participant received only the first dose of cisplatin due to a significant 
deterioration in hearing. Pre- and post-treatment data for these participants, along with 
that of the participant who received the largest total dose of cisplatin, are presented in 
detail. 
3.5.1 Participant 5 
Participant 5 is a 61;8 year old male who was diagnosed with SCC of the hypopharynx in 
2008. The participant was aged 60;6 years at the time of beginning concurrent cisplatin 
and irradiation therapy. One day prior to commencing treatment, the participant 
underwent baseline audiological assessment that included standard pure-tone 
audiometry, EHF pre-tone audiometry and tympanometry. Standard pure-tone 
audiometry showed normal hearing sloping to a mild loss at 8 kHz bilaterally. The PTA 
was 7.5 dB HL in the left ear, and 6.25 dB HL in the right ear. EHF pure-tone audiometry 
showed a moderate to severe sloping hearing loss in the left ear, with a loss of response at 
16 kHz, and a mild to moderately severe hearing loss in the right ear. EHF PTA was 56.25 
dB HL in the left ear and 42.5 dB HL in the right ear. Tympanometry yielded a type ―A‖ 
tympanogram bilaterally, consistent with normal middle ear pressure and compliance. 
Participant 5 received one dose of 180 mg cisplatin on day one of the treatment protocol. 
On day 23, the participant underwent a follow-up audiological assessment prior to 
receiving the second dose. Standard pure-tone audiometry showed deterioration of high-
frequency thresholds with a decrease of 25 dB at 4 kHz, 35 dB at 6 kHz and 55 dB at 8 
kHz in the left ear, and15 dB at 4 kHz, and 25 dB at 8 kHz in the right ear. Bone 
conduction suggested a conductive component at 4 kHz bilaterally. EHF pure-tone 
audiometry showed a 35 dB decrease at 9 kHz, 10 kHz and 11.2 kHz, with a loss of 
response at 12.5 kHz, 14 kHz and 16 kHz in the left ear. EHF pure-tone audiometry also 
showed a 45 dB decrease at 9 kHz, 35 dB at 10 kHz, 45 dB at 11.2 kHz and loss of response 
at 12.5 kHz in the right ear. Analysis of thresholds in relation to the ASHA criteria 
indicated a significant cochleotoxic change, fulfilling all three criteria bilaterally. 
Tympanometry remained stable indicating no middle ear effusion. It was also noted in the 
patient file that participant 5 had signs of renal dysfunction and had experience 
significant nausea and vomiting. For these reasons, the second cisplatin dose was reduced 
by 25% to 130 mg. The third dose was withheld due to acute renal failure. No further 
monitoring audiological assessments were carried out. 
Post-treatment assessment was carried out for the purpose of this research in January 
2010. During questioning, the participant reported a gradual bilateral hearing loss prior 
to beginning treatment but noted a significant deterioration since treatment. He reported 
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difficulty hearing in group situations and in environments with background noise. He 
commented that he now turns the television volume up to a level that his wife is not 
comfortable with. Participant 5 reported experiencing a high pitched, ringing tinnitus 
although he was unsure of the time of onset and whether it had changed since undergoing 
treatment. He reported a 10 year history of occupational noise exposure for which he 
wore hearing protection. Standard pure-tone audiometry showed normal hearing sloping 
steeply to a severe hearing loss bilaterally. Bone conduction results indicate a conductive 
component at 4 kHz in the left ear, and at 1, 2, and 4 kHz in the right ear. Standard PTA 
was 13.75 dB HL in the left ear, and 21.23 dB HL in the right ear. EHF pure-tone 
audiometry showed a severe rising to a moderately-severe hearing loss in the left ear and 
a severe to moderately-severe flat hearing loss in the right ear. EHF PTA was 85 dB HL in 
the left ear, and 82.5 dB HL in the right ear. Analysis of thresholds in relation to the 
ASHA criteria indicated a significant cochleotoxic change, fulfilling criteria 1 and 2 
bilaterally. Otoscopy showed significant wax in the right ear. Tympanometry yielded type 
―A‖ tympanograms bilaterally, consistent with normal middle ear pressure and 
compliance. Speech audiometry at a presentation level of 45 dB HL in the left ear and 50 
dB HL in the right ear yielded 97% and 100% respectively. Speech presentation at 30 dB 
HL gave 94%, and 63% at a level of 20 dB HL in the left ear. In the right ear, a 
presentation level of 35 dB HL and 25 dB HL gave 100% and 88% respectively. DPOAEs 
were present in the left ear at 2, 2.25, 2.5, 4.5 and 9.25 kHz and from 2 to 6.125 in the 
right ear. Ipsilateral acoustic reflexes were unable to be tested due to difficulty 
maintaining a hermetic seal. Audiometric data for participant 5 are detailed in Figure 3.8.
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Figure 3.8: Illustration of hearing thresholds in decibel hearing level (dB HL) at 0.25 to 16 
kHz for the right ear (top) and left ear (bottom). Thresholds are shown as a function of 
time from the initial cisplatin dose (0 months) to post-treatment assessment. The vertical 
lines indicate cisplatin doses. Horizontal bar indicates period of irradiation. Dashed 
coloured lines indicate extended high-frequency thresholds. No response at the limits of 
the audiometer is indicated by an arrow, with those intensities joined by dotted lines.
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3.5.2 Participant 21 
Participant 21 is a 58;0 year old male who was diagnosed with SCC of the oropharynx in 
2008. The participant was aged 56;6 years at the time of beginning concurrent cisplatin 
and cranial irradiation therapy. Two days prior to commencing treatment, the participant 
underwent audiological assessment that involved standard pure-tone audiometry, EHF 
pure-tone audiometry, and tympanometry. Standard pure-tone audiometry showed 
normal hearing sloping to moderate hearing loss bilaterally. Bone conduction results 
indicate a conductive component at 4 kHz. The PTA was 7.5 dB HL in the left ear and 
11.25 dB HL in the right ear. EHF pure-tone audiometry showed a moderate to 
moderately-severe relatively flat loss bilaterally. The EHF PTA was 56.25 dB HL in the left 
ear and 58.75 dB HL in the right ear. Tympanometry yielded type ―A‖ tympanograms 
bilaterally, consistent with normal middle ear pressure and compliance. 
Participant 21 received one dose of 219 mg cisplatin on day one of the treatment protocol. 
On day 22, he received the second 219 mg dose of cisplatin. The day following (day 23) he 
underwent repeat audiological assessment consisting of standard pure-tone audiometry, 
EHF pure-tone audiometry and tympanometry. Standard pure-tone audiometry showed a 
15 dB deterioration at 4 kHz in the right ear. Bone conduction results were consistent 
with a conductive component. EHF pure-tone audiometry showed a deterioration of 15 dB 
at 11.2 kHz, 25 dB at 12.5 kHz and loss of response at 14 kHz and 16 kHz in the right ear. 
EHF pure-tone audiometry also showed a 15 dB deterioration at 14 kHz and a loss of 
response at 16 kHz in the left ear. Tympanometry yielded a type ―A‖ tympanogram in the 
left ear, consistent with normal middle ear pressure and compliance, and a type ―C‖ 
tympanogram in the right ear, consistent with negative middle ear pressure and resulting 
in a retracted tympanic membrane. Analysis of thresholds in relation to the ASHA criteria 
indicated a significant cochleotoxic change bilaterally, fulfilling criterion 2 for the left ear 
and both criteria 1 and 2 for the right ear. On day 42, participant 21 received his third and 
final dose of 219 mg cisplatin, bringing the total dose to 657 mg. This is the highest dose 
received by any of the 23 participants involved in this study. The irradiation therapy 
ceased 7 days later. 
Approximately three months later in February 2009, participant 21 underwent a follow-
up audiological assessment involving standard pure-tone audiometry, EHF pure-tone 
audiometry, and tympanometry. Standard pure-tone audiometry did not show any 
significant change in the left ear. In the right ear, there was a significant deterioration of 
15 dB HL at 0.25 kHz and 3 kHz, 20 dB HL at 4 kHz, and 15 dB HL at 6 kHz and 8 kHz. 
Bone conduction at 4 kHz in the right ear suggested a conductive component and was not 
significantly different from the previous test. EHF pure-tone audiometry in the left ear 
showed a deterioration of 20 dB HL at 9 kHz, and 15 dB HL at 10 kHz. There was a 
significant improvement of hearing thresholds at 14 kHz and 16 kHz, with an 
improvement of 15 dB HL and at least 25 dB HL respectively. In the right ear, there was a 
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35 dB HL deterioration at 9 kHz and 10 kHz, 15 dB HL at 11.2 kHz, and a loss of response 
at 12.5 kHz and 14 kHz. Tympanometry results were similar to the previous test with a 
type ―A‖ tympanogram in the left ear, and a type ―C‖ tympanogram in the right ear. 
Analysis of thresholds in relation to the ASHA criteria indicated a significant cochleotoxic 
change bilaterally, this time fulfilling criteria 1 and 2 in the left ear, and all three in the 
right ear. It is important to emphasise that, although there was middle-ear dysfunction 
which probably influenced the right ear thresholds, the 4 kHz bone conduction results 
show a 15 dB shift, although this is still not enough to fulfil the first ASHA criterion at that 
frequency. 
Further audiological assessment was carried out for the purpose of this research in March 
2010. The participant reported a gradual hearing loss since receiving treatment. He 
reported difficulty hearing in group situations and in noisy environments he relies on 
lipreading. He also described significant difficulty watching the television. Participant 21 
reported unilateral tinnitus in his right ear that sounds like a ―low pitch sea noise‖. He 
was unsure of the onset but had noticed an increase in severity since starting treatment. 
He also reported an occasional feeling of being on uneven ground that he first noticed 
after treatment. He did not describe any symptoms of vertigo or nausea. In addition, 
participant 21 described a feeling of aural pressure or fullness in his right ear that he 
believed developed whilst having treatment and lasted approximately three to four 
months. This was thought to be caused by otitis media with effusion. He reported a 15 
year history of occupational noise exposure during which time he wore hearing 
protection. Standard pure-tone audiometry showed normal hearing sloping to a mild 
hearing loss in the left ear, and normal hearing sloping to a moderate loss in the right ear. 
Bone conduction results indicate a conductive component at 4 kHz in the right ear. 
Standard PTA was 7.5 dB HL in the left ear and 15 dB HL in the right ear. EHF pure-tone 
audiometry showed a moderate to moderately-severe flat loss bilaterally. EHF PTA was 
57.5 dB HL in the left ear, and 63.75 dB HL in the right ear. Tympanometry yielded a type 
―A‖ tympanogram in the left ear, consistent with normal middle ear pressure and 
compliance, and a type ―C‖ tympanogram in the right ear, indicating negative middle ear 
pressure and resulting in a retracted tympanic membrane. Speech audiometry at a 
presentation level of 35 dB HL in the left ear and 40 dB HL in the right ear yielded 94% 
and 100% respectively. Speech presentation at 20 dB HL resulted in 80% and 13% at 10 
dB HL in the left ear. In the right ear, speech presentation at 25 dB HL and 15 dB HL 
resulted in 84% and 33% respectively. DPOAEs were present from 2 to 4.5 kHz and at 
6.125 kHz and 9.250 kHz in the left ear. In the right ear they were present from 2 to 4.062 
kHz, and at 7.5 kHz and 9.250 kHz. Ipsilateral acoustic reflexes were present at normal 
presentation levels from 0.5 to 2 kHz and absent at 4 kHz bilaterally. Analysis of 
thresholds in relation to the ASHA criteria indicated a significant cochleotoxic change in 
the right ear only, fulfilling criterion 2 only. Audiometric data for participant 21 are 
detailed in Figure 3.9. 
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Figure 3.9: Illustration of hearing thresholds in decibel hearing level (dB HL) at 0.25 to 16 
kHz for the right ear (top) and left ear (bottom). Thresholds are shown as a function of 
time from the initial cisplatin dose (0 months) to post-treatment assessment. The vertical 
lines indicate cisplatin doses. Horizontal bar indicates period of irradiation. Dashed 
coloured lines indicate extended high-frequency thresholds. No response at the limits of 
the audiometer is indicated by an arrow, with those intensities joined by dotted lines. 
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3.5.3 Participant 22 
Participant 22 is a 52;10 year old male who was diagnosed with SCC of the oropharynx in 
2005. The participant was aged 48;9 years at the time of beginning concurrent cisplatin 
and irradiation therapy. Eight days prior to commencing treatment, the participant 
underwent audiological assessment that involved standard pure-tone audiometry, EHF 
pure-tone audiometry and tympanometry. Standard pure-tone audiometry showed 
normal hearing sloping to a moderate mixed loss in the left ear, and normal hearing 
sloping to a mild sensorineural hearing loss in the right ear. The PTA was 20 dB HL 
bilaterally. EHF pure-tone audiometry showed a moderate to moderately-severe hearing 
loss with a loss of response above 14 kHz in the left ear. In the right ear, testing showed a 
moderate sloping to a severe hearing loss with a loss of response above 12.5 kHz in the 
right ear. Tympanometry yielded a type ―A‖ tympanogram in the left ear, consistent with 
normal middle ear pressure and compliance, and a type ―Ad‖ in the right ear, consistent 
with greater than normal compliance. 
Participant 22 received one dose of 187 mg cisplatin on day one of the treatment protocol. 
Twenty days later the participant complained of hearing loss and was subsequently sent 
for audiological assessment. Standard pure-tone audiometry showed deterioration of 
high-frequency thresholds with a decrease of 15 dB at 8 kHz in the left ear, and 15 dB at 4 
kHz, 30 dB at 6 kHz and 40 dB at 8 kHz in the right ear. EHF pure-tone audiometry 
showed a 20 dB decrease at 10 kHz and 11.2 kHz in the left ear, and a 15 dB decrease at 9 
kHz and 10 kHz and loss of response at 11.2 and 12.5 kHz in the right ear. Tympanometry 
remained stable, indicating no middle ear effusion. Analysis of thresholds in relation to 
the ASHA criteria indicated a significant cochleotoxic change, fulfilling criteria 1 and 2 
bilaterally. Due to this change in hearing, the second dose was withheld. Twenty one days 
later the participant was reassessed prior to the scheduled third cisplatin dose. Standard 
audiometry indicated further deterioration in the right ear only, with an additional 
decrease of 15 dB at 0.25 kHz and 0.5 kHz, 20 dB at 2 kHz and 15 dB at 4 kHz. Bone 
conduction results indicated this was a mixed hearing loss. EHF audiometry did not show 
any significant change (≥ 15 dB) in hearing thresholds in either the left or right ear. 
Tympanometry remained stable in the right ear but suggested reduced compliance in the 
left ear (type ―As‖ tympanogram). Analysis of thresholds in relation to the ASHA criteria 
continued to indicate a significant cochleotoxic change, fulfilling criteria 1 and 2 
bilaterally The third dose was also withheld due to the further deterioration in hearing on 
the right side. 
Post-treatment assessment was carried out for the purpose of this research in January 
2010. The participant reported sudden hearing loss, particularly in his right ear that he 
believed developed with cisplatin treatment. He reported difficulty hearing in group 
situations and when there is background noise. He felt that he had the television and 
radio turned up louder than other family members would like. Participant 22 also 
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reported unilateral tinnitus in his left ear, the onset of which coincided with the single 
dose of cisplatin. He described it as a high pitch ringing that was of minimal annoyance. 
He had a history of occupational noise exposure of approximately 20 years duration, but 
did not wear hearing protection. Standard pure-tone audiometry showed a mild to 
moderate sloping sensorineural hearing loss in the left ear, and a mild to moderately-
severe sloping mixed hearing loss in the right ear. Standard PTA was 32.5 dB HL for the 
left ear and 30 dB HL for the right ear. EHF pure-tone audiometry showed a moderate to 
moderately-severe flat hearing loss in the left ear and a severe to profound hearing loss in 
the right ear. EHF PTA was 56.25 dB HL in the left ear and 86.25 dB HL in the right ear. 
Tympanometry yielded a type ―A‖ tympanogram in the left ear, consistent with normal 
middle ear pressure and compliance, and a type ―Ad‖ tympanogram in the right ear, 
consistent with increased compliance. Speech audiometry at a presentation level of 65 dB 
HL yielded 94% in the left ear and 100% in the right ear. Speech presentation at 55 dB HL 
and 40 dB HL in the left ear yielded 74% and 54% respectively. Speech presentation at 50 
dB HL and 35 dB HL in the right ear yielded 80% and 21% respectively. DPOAEs were 
present in the right ear at 2, 2.5, 3.062, 4.062, 4.5 and 5.5 kHz, and in left ear at 2, 2.25, 
4.5 and 6.125 kHz. Ipsilateral acoustic reflexes were present at normal presentation levels 
in the left ear from 0.5 to 2 kHz and absent at 4 kHz. Reflexes were absent from 0.5 to 4 
kHz in the right ear. Analysis of thresholds in relation to the ASHA criteria indicated a 
significant cochleotoxic change, fulfilling criteria 1 and 2 bilaterally. Audiometric data for 
participant 22 are detailed in Figure 3.10. 
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Figure 3.10: Illustration of hearing thresholds in decibel hearing level (dB HL) at 0.25 to 
16 kHz for the left ear (top) and right ear (bottom). Thresholds are shown as a function of 
time from the initial cisplatin dose (0 months) to post-treatment assessment. The vertical 
lines indicate cisplatin doses. Dashed coloured lines indicate extended high-frequency 
thresholds. No response at the limits of the audiometer is indicated by an arrow, with 
those intensities joined by dotted lines. 
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3.5.4 Participant 23 
Participant 23 is a 55;3 year old male who was diagnosed with SCC carcinoma of the 
oropharynx at Christchurch Public Hospital in 2007. The participant was aged 52;9 years 
old at the time of beginning concurrent cisplatin and irradiation therapy. Prior to 
commencing treatment, the participant underwent audiological assessment that involved 
standard pure-tone audiometry, EHF pure-tone audiometry and tympanometry. Standard 
pure-tone audiometry showed normal hearing bilaterally with a PTA of 11.25 dB HL in his 
left ear and 17.5 dB HL in his right ear. EHF pure-tone audiometry showed a mild hearing 
loss bilaterally sloping to a moderate hearing loss in the right ear, and a moderately-
severe loss in the left ear. EHF PTA was 35 dB HL bilaterally. Tympanometry yielded type 
―A‖ tympanograms bilaterally, consistent with normal middle ear pressure and 
compliance. 
Participant 23 received two doses of 200 mg cisplatin, giving a total dose of 400 mg. The 
participant did not receive the scheduled third dose due to a significant deterioration in 
his health including septicaemia, neutropenia, respiratory failure and acute renal failure. 
The participant received a total irradiation dose of 74 Gy in 37 fractions (2 Gy per 
fraction). The participant had a history of chronic Hepatitis C. 
Post-treatment assessment was carried out for the purpose of this research in January 
2010. The participant reported gradual hearing loss that he first noticed since undergoing 
treatment for cancer. He believed he had experienced hearing loss in both ears and 
reported difficulty hearing when engaged in two-person conversations and group 
conversations, when watching television and when in situations with background noise. 
Standard pure-tone audiometry showed normal hearing steeply sloping to a severe 
sensorineural hearing loss bilaterally with a PTA of 30 dB HL in his left ear and 25 dB HL 
in his right ear. EHF pure-tone audiometry showed a severe hearing loss bilaterally with a 
loss of response at 12.5, 14 and 16 kHz in the left ear and at 16 kHz in the right ear. EHF 
PTA was 85 dB HL in the left ear and 88.75 dB HL in the right ear. Tympanometry was 
not performed due to significant wax and debris bilaterally. Speech audiometry at a 
presentation level of 45 dB HL yielded 100% in the right ear and 87% in the left ear. 
Speech presentation at 30 dB HL yielded 63% in the right ear and 50% in the left ear. 
Acoustic reflexes and DPOAEs were unable to be performed due to time constraints. 
Analysis of thresholds in relation to the ASHA criteria indicated a significant cochleotoxic 
change, fulfilling criteria 1 and 2 bilaterally. Audiometric data for participant 23 are 
detailed in Figure 3.11. 
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Figure 3.11: Illustration of hearing thresholds in decibel hearing level (dB HL) at 0.25 to 
16 kHz for the left ear (top) and right ear (bottom). Thresholds are shown as a function of 
time from the initial cisplatin dose (0 months) to post-treatment assessment. The vertical 
lines indicate cisplatin doses. Dashed coloured lines indicate extended high-frequency 
thresholds. No response at the limits of the audiometer is indicated by an arrow, with 
those intensities joined by dotted lines. 
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4 Discussion 
Cisplatin-induced ototoxicity is a significant clinical problem that can result in vocational, 
educational and social consequences. Currently there is no clinically-proven method to 
reduce or prevent this from occurring. In the present study, detailed post-treatment 
audiological assessment was performed in 23 patients who had previously received 
concurrent cisplatin and cranial irradiation therapy for the treatment of head and neck 
cancer. In addition, audiology files were examined and any previous audiometric data for 
the patients were analysed. The aims of this study were: 
1. To investigate the prevalence of ototoxicity in head and neck oncology patients who 
received cisplatin in combination with cranial irradiation; and 
2. Examine the current state of audiological monitoring for this population at a major 
New Zealand hospital. 
It is the author‘s hope that this study will increase audiologists‘ awareness of the impact 
of ototoxicity and the importance of comprehensive audiological monitoring with the 
potential of improving quality of life for oncology patients. 
A summary of the findings is provided below and is discussed in relation to the relevant 
literature. Following that, the clinical implications are presented, as well as limitations of 
the study and directions for future research. 
4.1 Cisplatin-induced ototoxicity 
Significant changes in hearing resulting from exposure to ototoxic agents, defined by the 
ASHA criteria of (1) ≥ 20 dB decrease at any one test frequency; (2) ≥ 10 dB decrease at 
any two adjacent test frequencies; or (3) loss of response at three consecutive test 
frequencies where responses were previously obtained, were observed in this study. In 
total, 93.8% of the participants who had undergone a baseline audiological assessment 
experienced significant cochleotoxic deterioration in hearing thresholds. This is 
comparable to previous studies which have reported rates as high as 75 – 100% 
(McKeage, 1995), although rates as low as 9% have also been noted (Rybak, 1981). The 
observed variability in the reported incidence of cisplatin ototoxicity may be influenced by 
treatment and patient-related factors. Factors such as larger cumulative dose (Brock, et 
al., 1991), younger and older age (Helson, et al., 1978; Li, et al., 2004), renal dysfunction 
(Rybak, Huang, et al., 2007), noise exposure (Bokemeyer, et al., 1998) and cranial 
irradiation (Low, et al., 2006) have been cited as variables that increase an individual‘s 
risk of ototoxicity. The influences of such factors are discussed in the following sections. 
In addition, differences in the criteria used to define ototoxicity may also affect the 
reported incidence. The ASHA (American Speech-Language-Hearing Association, 1994) 
criteria are the most widely used criteria used for determining a shift in pure-tone 
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thresholds. Clinical trials, however, list ototoxicity as an adverse event based on a grading 
system. The two most widely used grading scales in this respect are Brock‘s Hearing Loss 
Grades (Brock, et al., 1991) and the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) Ototoxicity Grades. Caution should be 
exercised when comparing incidence rates across studies, particularly those that do not 
use one of the aforementioned criteria, as differences may be attributed to false positive 
results due to criteria that are too stringent. 
4.1.1 The influence of cumulative and total dose 
There is agreement in the literature that cumulative doses greater than 400 mg/m2 places 
the patient at higher risk of developing ototoxicity. These studies are, however, often 
based on children and young adults with common paediatric malignancies such as 
osteosarcoma, medulloblastoma and neuroblastoma (Knight, Kraemer, & Neuwelt, 2005). 
Reports of hearing deterioration from smaller doses are not uncommon (Rybak, 1981). 
Helson et al., (1978) found high-frequency SNHL in patients receiving cisplatin in excess 
of 200 mg total dose while Schaefer et al., (1985) studied ototoxicity in a sample of 100 
head and neck cancer patients ranging in age from 51 to 69 years. They concluded that 
patients receiving a total dose more than 400 mg of cisplatin over a period of six weeks or 
longer are at risk of developing ototoxicity and should be routinely screened. In the 
current study, the maximum cumulative dose for any participant was 300 mg/m2. 
Fourteen participants, however, received a total dose of 400 mg or more over a period of 
six weeks, placing them at higher risk of developing ototoxicity. From the group of 16 
participants who had a pre-treatment assessment, it was noted that there were similarly 
high proportions of cochleotoxicity (based on any one of the three ASHA criteria being 
met) between those who had received a total dose of 400 mg or more and those who 
received less than 400 mg. Specifically, all 6 participants who received under 400 mg 
experienced significant hearing deterioration, while 9 out of the 10 participants who 
received 400 mg or greater experienced significant hearing deterioration. This indicates 
that there is no significant effect of total cisplatin dose observed in this study, but this 
may be due to the small sample size. 
4.1.2 The influence of renal dysfunction 
Two participants (participant 5 and participant 23) were noted to have renal dysfunction 
during their treatment, and both experienced significant cochleotoxicity based on the 
ASHA criteria. The literature indicates patients with renal function have poor creatinine 
clearance which leads to increased serum active cisplatin levels. In contrast, a recent 
study has found plasma cisplatin concentration in patients with renal dysfunction about 
the same as patients with normal renal function (Matsumoto, 2008). 
4.1.3 The influence of noise exposure 
In the present study, over 90 percent of participants reported exposure to significant 
levels noise through their occupation. NIHL is the second most common SNHL after 
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presbycusis, and has become one of the most important occupational problems since the 
industrial revolution (Konings, Van Laer, & Van Camp, 2009). There are three types of 
changes in hearing status that may occur following exposure to either recreational or 
occupational noise. These are referred to as temporary threshold shift (TTS), permanent 
threshold shift (PTS) and acoustic trauma (Feuerstein, 2002). TTS is a temporary 
reduction in hearing sensitivity resulting from exposure to sound above 85 dBA, and 
represents transient hair cell dysfunction (Rabinowitz, 2000). Other symptoms may 
include a subjective feeling of aural fullness and tinnitus (Feuerstein, 2002). This 
temporary hearing loss typically recovers within 16 to 24 hours of the noise exposure 
(Thorne et al., 2008), and is attributed to the synaptic repair and reconnection of inner 
hair cells via new dendritic processes (Prasher, 1998). PTS occurs with chronic noise 
exposure and can result from incomplete recovery of TTS. Damage to the cochlear results 
from metabolic decompensation (Konings, et al., 2009) and includes disruption to the 
stereocilia, swollen nuclei, swollen mitochondria, cytoplasmic vesiculation and 
vacuolization. Progressive damage may lead to degeneration of nerve fibres and changes 
within the central auditory system (Feuerstein, 2002). Acoustic trauma occurs following 
acute exposure to noise intensities above 130 dB SPL, causing mechanical destruction of 
the organ of Corti (Konings, et al., 2009). Damage may also extend to tympanic 
membrane perforation and ossicular fractures (Feuerstein, 2002). It appears there is 
large individual susceptibility to NIHL. This individual variability is an indication that 
NIHL does not have a single causative factor, but is in fact, a complex condition caused by 
an interaction of environmental and genetic factors. Environmental factors have been 
well researched and include exposure to organic solvents and heavy metals (Morata, 
Dunn, & Seiber, 1994), age (Rosenhall, 2003), extreme temperatures, and vibration 
(Prasher, 1998). Genetic factors associated with NIHL are less well known. Research into 
this area has examined the role of oxidative stress, K-recycling pathway, and heat shock 
proteins (Konings, et al., 2009). 
It has been noted that concurrent noise exposure may potentiate the ototoxicity of 
cisplatin. Using a chinchilla model, (Boettcher, Henderson, Gratton, Danielson, & Byrne, 
1987) showed that even mild noise exposure during treatment significantly increases the 
risk of permanent hearing loss (ANOVA: p < 0.0001). In particular, the interaction 
between noise and cisplatin was found to occur even in cases where cisplatin 
administration alone did not result in deterioration of thresholds. This is supported by 
Gratton, Salvi, Kamen and Saunders (1990) who demonstrated an increased risk of hair 
cell damage with noise exposure between 70 – 85 dB SPL. Initially noted at the highest 
test frequency, as noise level increases, cochlear damage spreads upwards to affect the 
mid-frequencies. The effect of prior noise exposure on thresholds is somewhat 
controversial with Laurell and Borg (1986) showing no effect. This finding may 
potentially be due to maximal OHC dysfunction already occurring as a result of noise 
exposure and therefore cisplatin administration may not result in further damage unless 
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the dose is high enough to begin causing damage to IHCs. In contrast, however, a history 
of noise exposure has been independently correlated with both subjective and objective 
hearing loss resulting from cisplatin treatment (Bokemeyer, et al., 1998). 
In the present study, participants were questioned about their history of noise exposure 
but were not asked whether they had continued to have significant noise exposure during 
or directly following treatment. It is therefore difficult to draw any conclusions about the 
possible effect of noise exposure on the high prevalence of cisplatin-induced ototoxicity 
found in this study. 
4.1.4 The influence of cranial irradiation 
Due to the nature of the treatment protocol, all 23 participants received cranial 
irradiation. Eighteen of the 23 participants received a total irradiation dose of 70 Gy in 35 
fractions (2 Gy per fraction). This dosage of cranial irradiation alone has been shown to 
induce ototoxicity in at least 33% of patients (Raaijmakers & Engelen, 2002) and it has 
been shown that patients receiving concurrent cisplatin chemotherapy have a greater risk 
than those receiving only irradiation treatment (Low, et al., 2006). Of the 16 participants 
who had a pre-treatment assessment, 11 received 70 Gy in 35 fractions, while 3 
participants received a lower dose of 60 Gy in 30 fractions. A comparison between the two 
groups showed that both groups yielded similarly high proportions of participants who 
experienced cochleotoxicity based on any one of the three ASHA criteria. Specifically, all 
three participants who received the lower irradiation dose experienced cochleotoxicity, 
while 11 of the 12 participants who received the higher dose of irradiation experienced 
cochleotoxicity. Once again, this indicates that there is no significant effect of total 
irradiation dose observed in this study. This may be due to the small sample size, and also 
due to the common effect of the cisplatin therapy. 
4.1.5 The influence of loop diuretics 
Three of the participants (participants 2, 10 and 12) were given a single dose of the loop 
diuretic furosemide. This was administered to ameliorate facial swelling that had resulted 
from the irradiation therapy and prevented the correct fit of the treatment mask. Loop 
diuretics in isolation are known to produce a dose-related, usually reversible ototoxicity in 
6–7% of patients, primarily affecting those with renal dysfunction (Mudd, Edmunds, 
Glatz, Campbell, & Rybak, 2008). This occurs by inhibiting potassium transport, causing 
edema of the epithelium of the stria vascularis (Jordan & Roland, 2000). There is some 
evidence to suggest loop diuretics may augment cisplatin cochleotoxicity (Brummett, 
1980). Furosemide ototoxicity typically occurs with total daily IV doses greater than 240 
mg, and serum concentrations greater than 50 mg/L. (Seligmann, et al., 1996). In patients 
with renal dysfunction, oral administration of furosemide doses between 160 to 800 
mg/day has resulted in ototoxicity (Keefe, 1978). Furosemide ototoxicity is also 
dependent on the rate of infusion. IV administration of large doses (>120 mg) at a rate 
not exceeding 4 mg/min has been shown to avoid hearing loss (Rybak, 2007). In this 
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study, the administered doses of furosemide are considered low and therefore would not 
be expected to affect hearing thresholds in the short or long term. The rate of 
administration that was used in these patients, however, is unclear. 
4.1.6 Tinnitus 
In the present study, almost half of the sample reported tinnitus that had either begun or 
increased in severity as a result of treatment. This is higher than previously reported 
prevalence rates of 12–37% in other studies of cisplatin-induced ototoxicity (Bokemeyer, 
et al., 1998). The prevalence of chronic tinnitus in adults in the general population is 
estimated to fall in the range of 10–15% (Henry, Dennis, & Schechter, 2005) affecting a 
higher proportion of adults aged over 60 years compared with younger adults aged 20 – 
30 years (Eggermont & Roberts, 2004). There also appears to be a relatively equal 
distribution between males and females (Crummer & Hassan, 2004). Most cases of 
chronic tinnitus are associated with hearing loss that is induced by noise exposure or the 
aging process, although medications are frequently associated with temporary or 
permanent tinnitus. The mechanism responsible for tinnitus is poorly understood even in 
cases when a causal event seems obvious. It is thought that exposure to ototoxic agents 
may affect hair cells, the vestibulocochlear nerve, or their central nervous connections 
(Crummer & Hassan, 2004). There is some evidence that tinnitus is the result of changes 
in spontaneous activity in the auditory system (Eggermont & Roberts, 2004). Cisplatin 
administration in hamsters has been associated with an increase in spontaneous neural 
activity (hyperactivity) in the dorsal cochlear nucleus DCN (Kaltenbach et al., 2002). In 
particular, animals with severe OHC loss displayed well-developed hyperactivity, mainly 
in the medial (high-frequency) half of the DCN. This pattern is consistent with OHC loss 
occurring mainly in the basal half of the cochlea. 
In addition, there is a strong psychological component to tinnitus. This is illustrated in 
cases where the emergence of intrusive tinnitus occurs after the underlying medical 
condition and is triggered by seemingly unrelated factors such as emotional stress, 
psychological factors, bereavement, unemployment or various physical or mental illnesses 
(Henry, et al., 2005). These factors may also impact upon the perceived severity of the 
tinnitus. There is little doubt that undergoing treatment for cancer is a particularly 
stressful time, both emotionally and physically, and this aspect cannot be excluded as a 
contributing factor to the relatively high rate of tinnitus experienced in the study sample. 
4.1.7 Time course of cochleotoxicity 
Cisplatin-induced ototoxicity typically manifests as irreversible, progressive, bilateral, 
high frequency SNHL associated with tinnitus (Daldal, et al., 2007). Progression of 
hearing loss has been reported in 21% of patients, with deterioration continuing for up to 
26 months after the completion of cisplatin therapy (Knight, et al., 2005). Bertolini et al., 
(2004) investigated the severity and evolution of hearing loss in 120 survivors of 
childhood cancer. Median follow-up pure-tone audiometry was 7 years post treatment 
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and showed deterioration of hearing in 37% of patients treated with cisplatin, and in 43% 
of patients treated with cisplatin plus carboplatin. Progression of hearing loss was seen up 
to 136 months after the completion of therapy. Interestingly, hearing loss was noted in 
patients who had normal hearing immediately post treatment. The period of time in 
which stabilisation of hearing thresholds occur is unknown, however, cisplatin has been 
detected in plasma proteins up to six months after completion of therapy (Mudd, et al., 
2008). Participant 22 displayed continuing deterioration of hearing thresholds for 
approximately two months after the cessation of treatment (Figure 3.10). Participant 22 
did not receive doses 2 and 3 due to significant changes in hearing that were measured 
approximately 3 weeks apart. Unfortunately no subsequent assessments were made in the 
period following and so it is uncertain whether his hearing stabilised shortly after the two 
month period or whether it continued to decline over a longer interval. Participant 23 also 
showed deterioration between the pre- and post-treatment assessments (Figure 3.11), 
however, due to the lack of follow-up assessment it is uncertain over what period of time 
this occurred. During the case history, participant 23 reported the gradual onset of 
hearing loss post treatment. 
Although the auditory deficits are usually permanent, limited recovery has been observed 
both clinically and experimentally. Comparison of audiograms obtained from 50 male 
genitourinary cancer patients from baseline to the 52nd week of cisplatin treatment 
showed complete recovery of thresholds in 2% of patients, partial recovery in 26% and no 
recovery in 54% (Aguilar-Markulis, Beckley, Priore, & Mettlin, 1981). Bokemeyer et al., 
(1998) also reported partial or complete reversibility of subjective and/or objective 
hearing loss. Results from Klis et al., (2002) show that the loss and recovery of cochlear 
sensitivity coincides with loss and recovery of the endocochlear potential. These 
fluctuations do not occur for every patient, with studies not showing any change for a 
period of five years (Brock, et al., 1991). In this study, participant 5 and participant 21 
experienced a temporary decline in hearing that fulfilled the third ASHA criteria but had 
recovered significantly before the post-treatment assessment. 
4.1.8 Vestibulotoxicity 
The cochleotoxicity of cisplatin is well documented in the literature, however, there are 
few reports concerning vestibular dysfunction resulting from cisplatin administration. In 
the present study, 17.4% of participants reported experiencing balance disturbances since 
receiving treatment. Clinically, cisplatin vestibulotoxicity is controversial. Vestibular 
complaints may be subtle or masked by symptoms commonly seen in patients receiving 
chemotherapy, such as nausea, vomiting and/or ataxia. Both temporary (Black, Gianna-
Poulin, & Pesznecker, 2001) and permanent (Schaefer, Wright, Post, & Frenkel, 1981) 
vestibular dysfunction in humans has been demonstrated by caloric testing. The targets of 
cisplatin vestibulotoxicity have been investigated in albino guinea pigs using the 
vestibulo-ocular reflex (VOR) (Sergi, Ferraresi, Troiani, Paludetti, & Fetoni, 2003). 
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Significant decreases in VOR gain have been observed (p = 0.014) and are attributable to 
both crista and macular hair cell damage. Histological preparations confirm this 
hypothesis showing slight vestibular hair cell loss in both macular and semicircular canal 
organs (Sergi et al., 2004). In contrast, transmission electron microscopy of cisplatin-
treated animals showed normal type I and type II hair cells with no evidence of blebbing, 
vacuolisation, loss of sterocilia and kinocilia or supporting cell damage (Schweitzer, 
Rarey, Dolan, Abrams, & Sheridan, 1986). Recently, proinflammatory cytokines are 
suggested to play a critical role in the pathogenesis of cisplatin-induced vestibulotoxicity 
(H. J. Kim et al., 2008). Overall, the vestibular epithelium appears more resistant to 
cisplatin injury although the reasons for this remain unknown. It appears that the slight 
vestibular dysfunction observed is consistent with the relatively low proportion of 
patients who experience vestibular symptoms.  
In addition, the vestibulotoxicity of irradiation should be considered. Cranial irradiation 
for the treatment and/or management of various head and neck cancers may involve 
parts of the ear. Vestibular function was investigated in 25 patients who had received 
between 28 and 51.2 Gy to the vestibular system (Gabriele, Orecchia, Magnano, Albera, & 
Sannazzari, 1992). Five patients experienced subjective vertigo or dizziness, while 11 
(44%) patients displayed vestibular abnormalities during assessment by 
electronystagmography (ENG). The amount of irradiation that the inner ear received in 
this study is unknown. 
4.2 The current state of audiological monitoring 
The results from this study showed that 30.4% of the individuals in this study did not 
have an audiological assessment prior to beginning their cisplatin treatment. One of the 
basic principles of cochleotoxicity monitoring is obtaining valid baseline data to measure 
any change in future thresholds (American Speech-Language-Hearing Association, 1994). 
Evidence in the literature indicates that the sensitivity of monitoring programmes are 
greatly increased by measuring EHF thresholds (Fausti, et al., 1993; Knight, et al., 2007). 
In this study, 87.5% of the participants who had baseline testing (i.e. 60.9% overall) had 
EHF audiometry included in the test battery. None of the baseline assessments included 
OAEs, acoustic reflexes or speech audiometry. Although not originally included in the 
ASHA cochleotoxicity criteria, investigations since have found that DPOAEs are 
particularly valuable for monitoring ototoxicity in patients who are unable to provide 
reliable behavioural thresholds due to age (Knight, et al., 2007) or illness (Reavis, et al., 
2008). 
Of the participants who received a pre-treatment assessment, 31.3% did not have any 
other follow-up assessments either during or after cisplatin therapy. It is recommended 
that participants undergo repeat assessments prior to each dose of cisplatin and then 
again at the completion of therapy to confirm any changes in hearing status (American 
Speech-Language-Hearing Association, 1994). Participant 21 only received one dose of 
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cisplatin due to significant deterioration in his hearing. He subsequently received a 
further two follow-up assessments, however, there was no repeat assessment to ascertain 
whether the hearing loss had stabilised or not. Participant 15 declined further doses of 
cisplatin due to a significant increase in tinnitus severity. Although tinnitus is associated 
with cisplatin-induced ototoxicity, the participant did not receive an audiological 
assessment at any stage.  
The results of this study showed that although the participants who perceived a change in 
their hearing were accurate; that is, there was a measureable change in thresholds based 
on ASHA criteria, some participants were unable to perceive a deterioration in their 
hearing when there had been a significant change. This highlights the importance of 
having an effective monitoring protocol in place rather than relying solely on patient 
report. Unfortunately, it is often communication difficulties that alert people to a decline 
in hearing, by which stage the ototoxic damage has infiltrated the frequency range 
considered important for speech. Fluent communication is particularly important for 
patients with life-threatening diseases such as cancer, and is a central quality of life issue. 
4.3 Other findings 
4.3.1 Impact of OHCs on threshold shifts 
In the present study, the greatest threshold shifts observed between pre- and post-
treatment audiograms occurred at 9 kHz for both the left and right ear. The smaller 
measured threshold shifts for frequencies 10 kHz and above may be explained by the 
presence of pre-treatment cochlear hearing loss in the higher frequencies as a result of 
factors such as aging and noise exposure (Barr-Hamilton, et al., 1991). Cochlear hearing 
loss can involve damage or loss of function of the OHCs, IHCs or both. These are referred 
to as motor losses, sensory losses or mixed hair cell losses, respectively. The OHCs play an 
active role in the cochlea, enhancing cochlear vibration approximately 1000-fold, 
equivalent to 60 dB (Patuzzi, 2009). Therefore, losses greater than 60-70 dB often 
indicate some loss of effective IHC or neural function (Vinay & Moore, 2007). The pattern 
of high-frequency loss typically observed in cases of cisplatin ototoxicity can be explained 
by the increased vulnerability of OHCs to free-radical damage at the base of the cochlea 
compared to OHCs at the apex of the cochlea. This is possibly due to lower levels of the 
cellular antioxidant glutathione (Sha, Taylor, Forge, & Schacht, 2001), and may increase 
the susceptibility of basal OHCs to the action of ROS. This theory may also apply to noise-
induced hearing loss (NIHL), where the formation of ROS has been shown to occur in 
response to noise trauma. The level of ROS has been shown to correspond with the 
intensity of exposure (Le Prell et al., 2003). In addition, BM vibration nearer the apex 
may be less affected by toxicity in the cochlea due to the reduced importance of the active 
process at lower frequencies. The minimal threshold changes at frequencies 10 kHz and 
above observed in this study may therefore be explained by prior damage and/or loss of 
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OHCs due to other factors such as noise exposure and possibly aging. In effect, the 
participants had already lost a large proportion of their active process at these EHF prior 
to cisplatin treatment, and so further cisplatin-induced injury through the formation of 
ROS had little impact on thresholds. At frequencies below 10 kHz, however, there was less 
OHC damage prior to treatment and therefore a greater effect was noted. These findings 
are in contrast to studies with samples consisting of children and young adults where 
threshold shifts are greatest with increasing frequency (e.g. de Almeida, Umeoka, Viera, & 
de Moraes, 2008), which is most likely due to these populations having intact OHCs prior 
to treatment. 
4.3.2 Effect of medical factors 
Hearing loss from ototoxicity is a complex disorder as there are often contributing factors 
such as age-related hearing loss, and noise exposure. In addition, certain medical 
conditions may also impact on the hearing loss observed, including cardiovascular disease 
(CVD), diabetes mellitus (DM), and head trauma. Other factors such as smoking and 
alcohol abuse have also been associated with hearing loss (Rosenhall, Sixt, Sundh, & 
Svanborg, 1993), however, as data were not collected on these determinants, they will not 
be discussed here. 
4.3.2.1 Cardiovascular disease 
In the present study, just under one third of the participants had at least one form of CVD 
including hypertension, cardiomyopathy, stroke and arrhythmia. A study by Gates, Cobb, 
D‘Agostino and Wolf  (1993) has shown a statistically significant association between CVD 
and hearing loss. This effect was noted to be greater for woman than men, and was more 
pronounced in the lower frequencies. Interestingly, metabolic presbycusis is associated 
with low-frequency hearing loss and is thought to result from microvascular disease 
leading to atrophy of the stria vascularis (Demeester, et al., 2009). A gender specific 
association has been observed, with middle-aged to elderly women with a self-reported 
history of myocardial infarction have been shown to be twice as likely to have cochlear 
impairment as women without a history of myocardial infarction (Torre, Cruickshanks, 
Klein, Klein, & Nondahl, 2005). This association was not observed in men. Over a quarter 
of the participants in this study had previously been diagnosed with hypertension. 
Hypertension and systolic (peak) blood pressure have also been associated with 
presbycusic changes in auditory status (Brant et al., 1996). A hypothesis put forward by 
Dai et al. (2004) proposes the role of hypoxia in the cochlea related to CVD events. 
Narrowing of the blood vessels that supply the cochlea may cause hypoxia of the inner ear 
and initiate a chain of events such as ischemia in the inner ear, malfunction of oxygen 
metabolism, reduction in the level of mitochondrial oxidative phosphorylation, elevation 
of free radicals and an accumulation of mitochondrial mutations. This may result in 
accelerated degeneration or death of cells in the organ of Corti and the nerve fibres of the 
inner ear, ultimately leading to decreased function of the acoustic neural system. 
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4.3.2.2 Diabetes 
One participant in the present study had type II insulin-dependent diabetes mellitus 
(IDDM). Unfortunately, this participant did not receive a pre-treatment assessment. In 
addition, the participant received follow-up assessments at another South Island hospital 
where EHF audiometry was not tested. Despite this, the post-treatment assessment 
showed that the participant did experience significant cochleotoxicity bilaterally, based on 
the earliest assessment that was carried out. The relationship between DM and SNHL has 
been examined for more than a century, although no lesions have been located and the 
underlying mechanism is currently unknown. Diabetes is associated, however, with an 
increased risk of hearing loss, particularly in adults under 50 years old (Austin et al., 
2009). Histological changes observed within type II diabetic cochleae include thickened 
vessels of the stria vascularis and BM, atrophy of the stria vascularis and loss of OHCs 
(Fukushima et al., 2006). These changes were greater in IDDM cochleae than those with 
the less severe noninsulin-dependent diabetes mellitus (NIDDM). 
4.3.2.3 Head trauma 
In the present study, 40% of participants reported significant head trauma during their 
life that rendered them unconscious and/or required admission to hospital. Hearing loss 
is a well-recognised consequence of head trauma. Although hearing loss is usually most 
pronounced in the high frequencies, the entire frequency range may be affected 
(Rosenhall, et al., 1993). Damage to the inner ear may include disruption to the 
membranous portion of the cochlea, disturbances in the circulatory system of the cochlea, 
or to haemorrhage into the fluids of the inner ear (Fitzgerald, 1996). Both peripheral and 
central damage has been illustrated in a rabbit model, with reduced DPOAE amplitudes 
and increased ABR wave I – III latencies (Danielidis et al., 2007). In addition, 
histopathologic examination of the temporal lobe and brainstem showed multiple 
haemorrhagic and necrotic areas, with oedema in the surrounding region, and severe 
damage to the vestibulocochlear nerve. Generally, hearing loss occurs immediately 
following the trauma and recovers somewhat over the next six months (Fitzgerald, 1996). 
In the present study, a single participant reported experiencing unilateral hearing loss 
following a blow to the head approximately 60 years earlier. Unfortunately, as there was 
no record of audiological assessment prior to the post-treatment assessment carried out 
for the purpose of this study, the magnitude of the hearing loss could not be quantified. 
4.3.3 4 kHz air-bone gap 
During the post-treatment assessment an air-bone gap equal to or greater than 15 dB at 4 
kHz was noted in six of the participants. In each case there was no other indication of a 
conductive component to their hearing loss; that is, no air-bone gap at other frequencies 
and type ―A‖ tympanograms, consistent with middle ear pressure and compliance. This 
phenomenon has been discussed in the literature, with speculation it is caused by acoustic 
radiation from the bone conductor reaching the test ear via air conduction thus increasing 
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the signal to the cochlea resulting in a better bone conduction threshold (Margolis, 2008). 
A study by Frank and Holmes (1981) found only a 1 dB difference between mastoid bone 
conduction thresholds at 4 kHz with the EAC plugged and unplugged. More recently, 
Stenfelt and Reinfeldt (2007) found that having the EAC plugged does in fact reduce ear 
canal pressure above 2 kHz, but does not affect bone conduction thresholds. Currently, 
the source of the aberrant 4 kHz air-bone gap is not thought to result from acoustic 
radiation, and remains unknown. 
4.4 Clinical implications 
Based on the results of the present study, there are two main clinical implications that are 
discussed below: participant‘s eligibility to receive funding for rehabilitation, and 
guidelines for the establishment of an ototoxicity monitoring programme. 
4.4.1 Hearing aid funding 
Obtaining baseline audiometric data and ensuring effective monitoring of hearing 
thresholds may impact upon an individual‘s ability to have a claim accepted by the 
Accident Compensation Corporation (ACC). Under ACC legislation, all New Zealand 
residents and visitors to New Zealand are eligible for comprehensive, no-fault personal 
injury cover provided by the Crown organisation. This includes cover for treatment injury 
(previously referred to as medical misadventure) which is defined as ―personal injury that 
is — suffered by a person — seeking treatment... receiving treatment from, or at the 
direction of, 1 or more registered health professional...; and (b) caused by treatment...‖ 
(Parliamentary Counsel Office, 2001, p. pg. 70). It might be argued that hearing loss 
resulting from cisplatin therapy constitutes a treatment injury. In the case of participant 
2, a claim for hearing loss as a treatment injury was submitted to ACC but was declined, 
apparently on the basis of having no pre-treatment audiometric data to confirm that there 
had been a decline in hearing thresholds as a result of cisplatin treatment. It does seem, 
however, that cisplatin-induced ototoxicity may not constitute a treatment injury. Further 
examination of the ACC act reveals that treatment injury is ―not a necessary part, or 
ordinary consequence, of the treatment, taking into account all the circumstances of 
treatment, including — the clinical knowledge at the time of treatment‖ (Parliamentary 
Counsel Office, 2001, p. pg. 70). Ototoxicity has long been recognised as a side effect of 
cisplatin treatment, and so could be conversely argued that the resulting hearing loss is in 
fact, an ordinary consequence of cisplatin treatment. The ambiguity of this definition and 
effect of cisplatin means that a case could, in theory, be argued either way and is very 
much dependent on the availability of evidence illustrating any change in hearing. 
Another important consideration is the potential impact of cisplatin-induced ototoxicity 
on an individual‘s ability to have a future claim accepted by ACC for NIHL. Individuals 
who have been exposed to high levels of noise may be eligible for complete funding of 
hearing aids and related consumables through ACC. Establishing that personal injury has 
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occurred as a result of noise exposure may prove difficult in individuals with no pre-
treatment audiogram. 
4.4.2 Recommendations for an ototoxicity monitoring programme 
This study indicates that monitoring for cochleotoxicity is not happening for all patients 
receiving treatment with cisplatin chemotherapy at Christchurch Hospital. Overall, this 
group of patients appear to be suffering substantial deterioration of their hearing as a 
result of their cancer treatment. Currently, the governing body for audiologists in New 
Zealand, the NZAS, do not have any standards of practice for ototoxicity monitoring (E. 
Hunter, personal communication, 20 May, 2010). This also appears to be the case for the 
Audiological Society of Australia and the British Society of Audiology. Recently, the 
American Academy of Audiology (AAA) developed a position statement and practice 
guidelines for ototoxicity monitoring (American Academy of Audiology, 2009). 
Over 90% of the participants for whom analysis of ototoxicity was possible, experienced a 
clinically significant deterioration of hearing thresholds as a result of concurrent cisplatin 
and cranial irradiation therapy. Data collected from patient files suggest that monitoring 
for ototoxicity is not currently routine procedure at Christchurch Hospital, with just 
under 70% of patients in the current study undergoing a baseline audiogram prior to 
commencing treatment. The purpose of this section is to clarify the clinical audiologist‘s 
role in ototoxicity monitoring, and suggest guidelines for the implementation of such a 
programme. 
4.4.2.1 Audiologists role in ototoxicity monitoring 
As discussed in the first chapter, the primary purpose of ototoxicity monitoring is early 
detection of hearing loss that may allow for appropriate intervention to minimise the 
effects and impact of hearing loss on the individual. For this to occur, it requires 
coordination with other medical personnel such as oncologists, radiologists and oncology 
nurses and may take the audiologist outside of their typical role. The position statement 
by AAA (2009) emphasises the role of the audiologist in the establishment and 
management of the programme particularly in the role of in-service education and 
interpretation of the results. In cases where ototoxicity is detected, the audiologist should 
be involved with the non-medical management side of the hearing loss. Assistance can 
include counselling, communication strategies, and prescribing amplification and/or 
assistive listening devices. Where amplification is not provided through the local hospital, 
patients should be made aware of the services provided by independent audiology clinics. 
4.4.2.2 Potential test battery 
There are three main approaches to ototoxicity monitoring which includes standard pure-
tone audiometry, EHF pure-tone audiometry, and OAE measurement (American 
Academy of Audiology, 2009). OAEs have gained in popularity as both a screening and 
diagnostic tool and there is increasing evidence supporting the clinical application of 
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OAEs in ototoxicity monitoring. DPOAEs provide a non-invasive, objective measure of 
cochlear function (Reavis, et al., 2008), are time efficient, have good test-retest reliability 
and are able to be carried out at a patient‘s bedside. Loss of DPOAE response indicates 
damage to OHCs before it is able to be detected with standard pure-tone audiometry 
(Ress, et al., 1999). Unlike pure-tone audiometry, however, there is no universally 
accepted criterion that indicates a significant decline in OHC function. A study by Knight 
et al., (2007) used a criterion of an 8 dB SPL decrease, based on Beattie, Kenworthy and 
Luna (2003) who reported that differences in DPOAE amplitudes must exceed 7 dB SPL 
at 1 to 4 kHz to be statistically significant at the 0.05 level. The same study by Knight et 
al., (2007) found that EHF pure-tone audiometry was more sensitive in detecting ototoxic 
changes than DPOAEs and standard pure-tone audiometry. DPOAEs were shown to 
detect changes before standard pure-tone audiometry, however. One consideration in 
selecting OAEs for testing is the restricted test frequency range of most OAE systems that 
is able to be measured. The equipment used in the present study tested up to 9.25 kHz. As 
per ASHA guidelines (American Speech-Language-Hearing Association, 1994), both 
immittance testing and speech audiometry should also be included, particularly in the 
baseline assessment and again at the post-treatment follow-up. 
4.4.2.3 Test protocol 
When deciding on a test protocol, in addition to test sensitivity and specificity, 
consideration must be given to the status of the patient (their ability to perform certain 
tasks and their pre-exposure hearing sensitivity), the time required to carry out the test 
and its analysis, the costs involved in performing and interpreting the test, and 
availability of equipment (Konrad-Martin et al., 2005). Patient responsiveness can be 
determined by physician or nurse reports, and can be classed into three general groups: 
responsive, limited responsive and non-responsive (American Speech-Language-Hearing 
Association, 1994). Responsive patients tend to be adults and older children who do not 
fatigue easily and are able to provide reliable behavioural responses. Limited responsive 
patients can only provide reliable behavioural responses for a limited period of time due 
to fatigue, illness and age-related factors. Small children may be classed as limited 
responsive. Non-responsive patients are those who are unable to provide behavioural 
responses and require assessment via objective measures only, such as DPOAEs and/or 
ABR testing. It is important to note that patients may fluctuate between these categories 
throughout the treatment and recovery phase and therefore it is important to include 
objective measures of auditory status in baseline evaluation for all patients. The following 
flow chart has been proposed by the National Center for Rehabilitative Auditory Research 
(Gordon, 2009). 
82 
 
Figure 4.1: Proposed protocol for ototoxicity monitoring (Gordon, 2009) 
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4.4.2.4 Tinnitus 
Tinnitus is a common side effect of many ototoxic drugs, including cisplatin (Seligmann, 
et al., 1996). In the current study, almost 50% of participants reported the onset or 
increase in severity of tinnitus. There is, however, no formal tinnitus monitoring 
procedures for use in an ototoxicity monitoring programme. In addition, tinnitus 
assessment methods are rarely reported in the literature. Self-report measures have been 
developed such as the Tinnitus Handicap Inventory (Newman, et al., 1996) and the TOMI 
(Fausti, et al., 2007). These surveys aim to quantify the impact of tinnitus on daily living 
and could be incorporated into a monitoring programme. 
4.4.2.5 Vestibulotoxicity monitoring 
The vestibulotoxicity of some drugs, such as particular aminoglycosides, is well 
established in the literature (Seligmann, et al., 1996). Despite this, there are no widely 
accepted guidelines for vestibulotoxicity monitoring. Like tinnitus, self-report measures 
such as the Dizziness Handicap Inventory (DHI) are available to provide a method of 
potentially detecting vestibulotoxicity (Jacobson & Newman, 1990). 
4.5 Limitations of the current study 
The criteria formulated by ASHA (1994) specify that any audiometric changes must be 
confirmed by a repeat assessment. This reliability check was not carried out in the current 
study for a number of reasons. Firstly, the period of data collection was limited 
considerably due to the significant delays involved with the initial research topic. 
Secondly, due to the large catchment area that Christchurch Hospital services for head 
and neck cancer, many of the participants did not reside locally making follow-up more 
difficult. The post-treatment assessments that were carried out were often scheduled for 
the same day as the patient‘s follow-up ENT and/or oncology appointment. This reduced 
additional travel and associated expense, particularly for participants who lived outside of 
Christchurch. 
It is important to consider the potential limitations of the study sample. Human 
populations tend to be heterogenous by nature. Consequently, in order to make 
generalisations and draw valid conclusions, a large sample size is needed to ensure the 
variations that exist in behavioural, psychological or physical attributes are present in the 
sample. In the current study, invitation letters were sent to 39 individuals who fulfilled 
the inclusion criteria as stated previously in the method chapter. Although the response 
rate (66.7%) achieved was above the average response rate of 61% for postal surveys and 
correspondence (de Vaus, 2002), there is the possibility that the individuals who 
responded may have done so because they were having difficulty with their hearing and 
were more interested in undergoing an audiological assessment. This may have led to a 
biased sample, with an overrepresentation of people who had perceived a decline in their 
hearing since treatment. In addition, the sample primarily consists of male participants 
(21 males and 2 females). Although this is representative of the male predominance in 
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head and neck cancers (Argiris, et al., 2008), it may have influenced the mean pre-
treatment hearing thresholds. Specifically, pure-tone thresholds may be elevated more so 
than if the sample consisted of an equal distribution of males and females, as males have 
greater hearing loss than their age-matched females with respect to age-related hearing 
loss (Van Eyken, et al., 2007). 
Another limitation of this study is the lack of information provided about the prior 
assessments. In most cases, the reliability of the patient, type of transducer used and 
observations from otoscopy were not reported. This may reduce the validity of comparing 
pre- and post-treatment assessments. It is also important to consider variability between 
pre- and post-treatment assessments that may be due to patient factors such as attention, 
wellness, and fatigue. 
A general limitation of ototoxicity monitoring is criteria that is used to define 
cochleotoxicity and is based on air conduction results alone. A limitation of this is that it 
does not account for fluctuations in middle ear status such as otitis media in paediatric 
populations or those undergoing cranial irradiation. In cases where no low frequency 
conductive component was measured, we have assumed there to be no significant 
conductive component in the EHF and therefore the thresholds were taken to represent 
cochlear function.  
4.6 Directions for future research 
The present study leads into a Phase III clinical trial to take place at Christchurch 
Hospital. This trial aims to investigate potential protective effects of IT dexamethasone 
administration against cisplatin-induced ototoxicity while preserving the 
chemotherapeutic actions. This trial will recruit patients diagnosed with some form of 
head and neck cancer who require at least two cycles of cisplatin therapy and concurrent 
cranial irradiation. 12 hours prior to the initial dose of cisplatin, all patients will have a 
baseline diagnostic audiological assessment including standard pure-tone audiometry 
(0.25 to 8 kHz), extended high-frequency audiometry (9 to 16 kHz), speech audiometry, 
tympanometry, DPOAEs, and evaluation of tinnitus using the TOMI. Approximately one 
hour before the administration of cisplatin, patients will receive IT injections of 24 mg 
dexamethasone and 0.9% saline into separate ears via bilateral myringotomies. Both the 
audiological assessment and IT injections will occur before each subsequent dose of 
cisplatin. At the completion of cisplatin therapy, the patients will undergo repeat 
audiological assessment at regular intervals to monitor any changes in their hearing 
status. 
This future research has the potential to affect hearing outcomes for patients receiving 
cisplatin therapy and cranial irradiation. The present study has shown this particular 
subset of patients to have relatively high rates of ototoxicity. The upcoming trial also has 
the potential to ameliorate the dose-limiting effect of ototoxicity. As illustrated in the 
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present study, cisplatin therapy has to be withheld because of deteriorating hearing or 
tinnitus. If IT dexamethasone is shown to exert a protective effect, it may allow patient 
who would otherwise have had their cisplatin therapy reduced or stopped, to continue 
with the standard dose of cisplatin, thus potentially improving outcome from treatment. 
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5 Summary 
Cisplatin –induced ototoxicity constitutes a significant clinical problem that can have far-
reaching consequences. In this study, over 90% of participants experienced significant 
deterioration of their hearing thresholds based on an internationally recognised criteria. 
This is at the higher end of the values reported in the literature and may be due to the 
relatively high dose of cisplatin administered and exposure to a well known risk factor, 
cranial irradiation. Along with hearing loss, nearly half of the participants suffered from 
onset of tinnitus, or a noticeable increase in the severity of their tinnitus. Balance 
disturbances were less reported and in line with current literature. 
This study found that despite the high proportion of patients experiencing ototoxicity, not 
all are receiving appropriate assessment and follow-up. Fluent communication is vital, 
particularly for a group of patients for whom quality of life is already compromised due to 
illness and fatigue. Consideration must be given, however, to the emphasis placed on 
carrying out a vigorous monitoring protocol for patients whom are already facing 
significant physical and emotional challenges. For a successful protocol to be established 
it requires an interdisciplinary approach with coordination between key personnel such as 
oncologist, radiologists, nurses, pharmacists and audiologists. 
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2 November 2009 
 
 
Dr David Gibbs 
Oncology Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
 
Dear Dr Gibbs 
 
Ethics Reference Number: URB/09/41/EXP 
Follow up audiological assessment of adult head and neck cancer 
patients treated with chemoradiation in the Christchurch area 
 
The above study has been given ethical approval by the Chairperson of 
the Upper South B Regional Ethics Committee. 
 
Approved Documents 
Study Protocol 
Letter to participants version 1.0, dated 12 October 2009 
Consent Form version 1.0, dated 12 October 2009 
 
Final Report 
The study is approved until 31 March 2010.  A final report is required at 
the end of the study and a report form to assist with this is available at 
http://www.newhealth.govt.nz/ethicscommittees.  If the study will not be 
completed as advised, please forward a report form and an application for 
extension of ethical approval one month before the above date. 
 
Amendments 
It is also a condition of approval that the Committee is advised if the study 
does not commence, or is altered in any way, including all documentation 
eg advertisements, letters to prospective participants. 
 
Please quote the above ethics committee reference number in all 
correspondence. 
 
It should be noted that Ethics Committee approval does not imply any 
resource commitment or administrative facilitation by any healthcare 
provider within whose facility the research is to be carried out.  The 
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organisation may specify their own processes regarding notification or 
approval. 
 
On behalf of the committee, I would like to take this opportunity to wish 
you all the best with your research. 
 
 
Yours sincerely 
 
 
 
 
 
 
Mrs Diana Whipp 
Upper South B Regional Ethics Committee Administrator 
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Follow up audiological assessment of adult oncology patients in the ChCh area. V 1.0, 12 
Oct 09 
 
 
Date 
 
 
 
 
Patient name 
Street address 
Suburb 
Town/city 
 
 
Dear (patient name inserted here), 
 
You have had treatment for head and neck cancer that involved you having radiation 
treatment and chemotherapy with cisplatin. We are studying the effects that this 
treatment has had on people‘s hearing and would like to invite you to take part in a 
research project called ―Follow up audiological assessment of adult head and neck 
oncology patients in the Christchurch area‖. 
 
If you would like to take part, you will undergo a complete hearing assessment. This 
assessment will take place at Christchurch Hospital in the Audiology department. It will 
consist of a some questions, a full hearing test (pure tone audiometry), a pressure test to 
assess how well your ear drum is moving (tympanometry), speech audiometry to assess 
how well you can hear words, and distortion product otoacoustic emissions (DPOAEs), a 
simple test which assesses the health of the organ of hearing. A summary of these hearing 
tests is on the next page. This assessment will take approximately 45 minutes to one hour. 
You will be given breaks in between tests if you feel that you need them. 
 
The results from this follow-up test will be compared to any hearing assessment that you 
had at the Hospital either before or during your cancer treatment to see whether there has 
been any change. We are interested in finding out about the number of people who had 
hearing testing before or during their cancer treatment, and the number of people who 
have a hearing loss as a result of their cancer treatment. Results from this research may 
help to improve patient care regarding hearing health. 
 
If this testing shows a hearing impairment, you will be able to discuss the options of 
rehabilitation (e.g. hearing aids) available to you if you wish. 
 
We will need to collect information such as your name and date of birth. We will ask you 
to sign a consent form for the collection of such information at the time of testing. The 
results of the research may be published, but no material which could personally identify 
you will be used in any reports on this study. All data collected will be treated with 
complete confidentiality. It is a requirement that all health research data must be stored 
for 10 years. 
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Follow up audiological assessment of adult oncology patients in the ChCh area. V 1.0, 12 
Oct 09 
 
 
This study has received ethical approval from the Upper South B Regional Ethics 
Committee. If you have any queries or concerns regarding your rights as a participant in 
this study, you may wish to contact a Health and Disability Advocate. 
Free phone: 0800 555 050 
Free fax: 0800 2 SUPPORT (0800 2787 7678) 
Email: advocacy@hdc.org.nz 
 
This assessment is not compulsory. By not taking part, your continuing/future healthcare 
will not be affected. You may bring a friend, family or whānau support with you to the 
appointment. 
 
If you have any further questions, please contact Dr David Gibbs at the Oncology Service, 
Christchurch Hospital. David can be contacted by phone, 0272900968 or by email, 
david.gibbs@cdhb.govt.nz. 
 
If you would like to have a follow-up hearing assessment and take part in this research, 
please contact Katrine Alchin to arrange an appointment. 
Phone: 027 3285770 
Email: kfn11@student.canterbury.ac.nz 
Or please return the enclosed response form in the prepaid envelope provided. 
 
 
Kind regards, 
 
 
 
Dr David Gibbs 
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Follow up audiological assessment of adult oncology patients in the ChCh area. V 1.0, 12 
Oct 09 
 
 
What’s involved in each part of the hearing assessment? 
History: The audiologist will ask you a series of questions. These may include 
your previous ear health, any hearing/communication concerns you may have, 
any family history of hearing loss, exposure to noise, tinnitus, balance or 
dizziness, facial numbness and other general health issues. 
Otoscopy: The audiologist will have a look in your ears using a special ear-torch 
called an "otoscope". This will tell us if your ears have any significant wax or 
debris in the ear canals and if your eardrum looks healthy. 
Tympanometry: A small rubber-tipped plug will be placed at the entrance to 
your ear canal, and you will hear a soft humming sound. The air pressure in the 
ear canal will then be altered slightly, which is painless (a bit like going up and 
down a hill in a car, but only for a few seconds). This will tell us how well your 
eardrum is moving, and whether you have any fluid in your middle ear. 
Pure-tone audiometry: You will be played a series of (mostly very quiet) tones 
(or ‗beeps‘) in each ear, and will be asked to tell the audiologist whenever you have 
heard a sound. This helps us to find the softest sounds you can hear, and let us 
know if you have a hearing loss or not. 
Speech audiometry: You will be played a recording of some of words (some at 
quiet levels) which you will be asked to repeat back. If you are unsure, you will be 
asked to guess. This will tell us how well you hear speech in each ear. 
DPOAEs: A small rubber plug (like the one used in the tympanometry test) 
placed at the entrance of your ear canal will play some moderate volume sounds 
into your ear. A microphone in the plug will listen for some special sounds that 
are generated by the ear itself. This will tell us how well your outer hair cells (a set 
of special sensory cells in the ear required for hearing) are working. 
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Date 
 
 
 
 
Patient name 
Street address 
Suburb 
Town/City 
 
 
Dear (patient name inserted here), 
 
In December 2009 we sent you a letter inviting you to take part in a research project 
called ―Follow up audiological assessment of adult head and neck oncology patients in the 
Christchurch area‖. You were invited because you have had treatment for head and neck 
cancer that involved you having radiation treatment and chemotherapy with cisplatin. 
The aim of this study is to investigate the effects that this treatment has had on people‘s 
hearing. 
 
We understand that your time is valuable, and that this may be a busy period for you. 
However, this research has the potential to improve the standard of hearing care for 
future patients. We are therefore taking this opportunity to ask you once more if you 
would like to take part in the study. Your participation would be greatly appreciated. 
 
If you would like to take part, you will undergo a complete hearing assessment. This 
assessment will take place at Christchurch Hospital in the Audiology department. It will 
consist of a some questions, a full hearing test (pure tone audiometry), a pressure test to 
assess how well your ear drum is moving (tympanometry), speech audiometry to assess 
how well you can hear words, and distortion product otoacoustic emissions (DPOAEs), a 
simple test which assesses the health of the organ of hearing. A summary of these hearing 
tests is on the next page. This assessment will take approximately 45 minutes to one hour. 
You will be given breaks in between tests if you feel that you need them. 
 
The results from this follow-up test will be compared to any hearing assessment that you 
had at the Hospital either before or during your cancer treatment to see whether there has 
been any change. We are interested in finding out about the number of people who had 
hearing testing before or during their cancer treatment, and the number of people who 
have a hearing loss as a result of their cancer treatment. Results from this research may 
help to improve patient care regarding hearing health. 
 
If this testing shows a hearing impairment, you will be able to discuss the options of 
rehabilitation (e.g. hearing aids) available to you if you wish. 
 
We will need to collect information such as your name and date of birth. We will ask you 
to sign a consent form for the collection of such information at the time of testing. The  
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results of the research may be published, but no material which could personally identify 
you will be used in any reports on this study. All data collected will be treated with 
complete confidentiality. It is a requirement that all health research data must be stored 
for 10 years. 
 
 
This study has received ethical approval from the Upper South B Regional Ethics 
Committee. If you have any queries or concerns regarding your rights as a participant in 
this study, you may wish to contact a Health and Disability Advocate. 
Free phone: 0800 555 050 
Free fax: 0800 2 SUPPORT (0800 2787 7678) 
Email: advocacy@hdc.org.nz 
 
This assessment is not compulsory. By not taking part, your continuing/future healthcare 
will not be affected. You may bring a friend, family or whānau support with you to the 
appointment. 
 
If you have any further questions, please contact Dr David Gibbs at the Oncology Service, 
Christchurch Hospital. David can be contacted by phone, 0272900968 or by email, 
david.gibbs@cdhb.govt.nz. 
 
If you would like to have a follow-up hearing assessment and take part in this research, 
please contact Katrine Alchin to arrange an appointment. 
Phone: 027 3285770 
Email: kfn11@student.canterbury.ac.nz 
Or please return the enclosed response form in the prepaid envelope provided. 
 
 
Kind regards, 
 
 
 
Dr David Gibbs 
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What’s involved in each part of the hearing assessment? 
History: The audiologist will ask you a series of questions. These may include 
your previous ear health, any hearing/communication concerns you may have, 
any family history of hearing loss, exposure to noise, tinnitus, balance or 
dizziness, facial numbness and other general health issues. 
Otoscopy: The audiologist will have a look in your ears using a special ear-torch 
called an "otoscope". This will tell us if your ears have any significant wax or 
debris in the ear canals and if your eardrum looks healthy. 
Tympanometry: A small rubber-tipped plug will be placed at the entrance to 
your ear canal, and you will hear a soft humming sound. The air pressure in the 
ear canal will then be altered slightly, which is painless (a bit like going up and 
down a hill in a car, but only for a few seconds). This will tell us how well your 
eardrum is moving, and whether you have any fluid in your middle ear. 
Pure-tone audiometry: You will be played a series of (mostly very quiet) tones 
(or ‗beeps‘) in each ear, and will be asked to tell the audiologist whenever you have 
heard a sound. This helps us to find the softest sounds you can hear, and let us 
know if you have a hearing loss or not. 
Speech audiometry: You will be played a recording of some of words (some at 
quiet levels) which you will be asked to repeat back. If you are unsure, you will be 
asked to guess. This will tell us how well you hear speech in each ear. 
DPOAEs: A small rubber plug (like the one used in the tympanometry test) 
placed at the entrance of your ear canal will play some moderate volume sounds 
into your ear. A microphone in the plug will listen for some special sounds that 
are generated by the ear itself. This will tell us how well your outer hair cells (a set 
of special sensory cells in the ear required for hearing) are working. 
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Version 1.0, 23 December 2009 
 
Response Form 
Follow up audiological assessment of adult head & neck oncology 
patients in the Christchurch area 
 
Yes, I would like to have a follow-up hearing assessment and take part in this research. 
Please contact me to arrange a suitable appointment time. 
Name:  
Address:  
 
Please tick preferred method of communication 
Phone 
(home): 
  
Phone (work):   
Cell phone:   
Email:   
 
Please send completed form in the prepaid envelope provided. Thank you. 
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Consent Form 
Follow up audiological assessment of adult head & neck oncology 
patients in the Christchurch area 
 
English I wish to have an interpreter Yes No 
Māori E hiahia ana ahau ki tetahi kaiwhakamaori/kaiwhaka pakeha korero Ae Kao 
Cook Islands Ka inangaro au I tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko kupu. E Nakai 
Sāmoan Ou te manaó ia I ai se faámatala upu Ioe Leai 
Tokelaun 
Ko au e fofou ki he tino ke fakaliliu te gagana Peletania ki na gagana o 
na motu o te Pahefika 
Ioe Leai 
Tongan Oku ou fiema'u ha fakatonulea Ioe Ikai 
Mandarin 我需要一个翻译 对 不对   
Japanese 通訳の人を希望します。 はい。 いいえ。 
Korean 통역이  필요 하세요? 네 아니오 
 
1. I have read and I understand the invitation letter dated 12 October 2009 for 
volunteers taking part in the above-named study. I have had the opportunity to 
discuss this study. I am satisfied with the answers I have been given. 
2. I have had the opportunity to use whānau support or a friend to help me ask 
questions and understand the study. 
3. I understand that taking part in this study is voluntary (my choice), and that I 
may withdraw from the study at any time without having to give a reason, 
including the withdrawal of any information I have provided. This will in no way 
affect my continuing and/or future health care. 
4. I have had this project explained to me in the invitation letter by Dr David Gibbs. 
5. I understand that my participation in this study is confidential and that no 
material which could identify me will be used in any reports on this study. 
6. I understand that the audiological assessment will be stopped if it should appear 
harmful to me. 
7. I have had time to consider whether or not to participate in the study. 
8. I know who to contact if I have any questions about the study in general. 
9. I would like a copy of the summarised results at the completion of the study 
yes/no 
10. I agree to my GP or other current provider being informed of my participation in 
this study/the results of my participation in this study 
yes/no 
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Participant to sign: 
 
I ……………………………………................................................................................... (full name) 
hereby consent to take part in this study  
Signature...................................................................................................................  
Date.............................. 
 
 
 
Researcher to sign: 
 
I.............................................……………………………………....................................... (full name) 
have explained the project to the participant. I believe consent was given freely by the 
participant and have witnessed the signing of the consent form above 
Signature...................................................................................................................  
Date.............................. 
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
50 dB HL
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30 dB HL
45 dB HL
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
20 dB HL
30 dB HL
45 dB HL
25 dB HL
35 dB HL
50 dB HL 100
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
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Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
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55 dB HL
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
10 dB HL
25 dB HL
40 dB HL
15 dB HL
30 dB HL
50 dB HL 100
97
47
94
84
36
102
Tested by:
Right
Type
Vol. (cc)
In
te
n
si
ty
 (
d
b
 H
L)
Ipsilateral Reflexes
0.25 0.5 1
In
te
n
si
ty
 (
d
b
 H
L)
Frequency (kHz)
8 9 10 11.2 12.5 140.25 0.5 2 41
22/02/2010
16
Frequency (kHz)
4 8
Right
TDHLeft
16
Air
   Right:
Left:
MEP (daPa)
Tympanometry
Right Left
Masked Air
Bone
Masked Bone
6812 7500 8375
Sound Ear Left
9250
4 kHz
100500 Hz
1 kHz
2 kHz
6125
Symbols
Right
No Response
Soundfield
UCL
0.7
1.4
A
20
0.8
1.3
SDT dB HL
Left
Speech Audiometry
AB word lists
Reliability
Good
Comp. (ml)
Transducer
9
95
105
100↓
90
85
95
95
11.2 12.5 14
A
20


     
55002500 2750
 
40623750
dB HL
Right
3062 3375
Distortion Product Otoacoustic Emissions (DPOAEs)
Left
F2(Hz) 2000 2250
Right
4500 5000
      
 
    
     
0
10
20
40
30
50
60
70
80
90
100
110
120
0
10
20
40
30
50
60
70
80
90
100
110
120
X
Participant # 13 67
Katrine Alchin
Significant wax
Clear
Left
X
< >
v w
S S
U U
 
R %
R %
R %
L %
L %
L %
R
L
 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
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Tested by:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
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Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
Participant:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
Pure-tone Audiometry Otoscopy
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
Date:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
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 Key: OAE present (SNR > 5 dB) OAE absent (≤ -10 dBSPL)  
Age: NHI:
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Pure-tone Audiometry Otoscopy
Participant:
30 dB HL
45 dB HL
30 dB HL
45 dB HL 100
63
87
50
102
Tested by:
Right
Type
Vol. (cc)
In
te
n
si
ty
 (
d
b
 H
L)
Ipsilateral Reflexes
0.25 0.5 1
In
te
n
si
ty
 (
d
b
 H
L)
Frequency (kHz)
8 9 10 11.2 12.5 140.25 0.5 2 41
29/01/2010
16
Frequency (kHz)
4 8
Right
TDHLeft
16
Air
   Right:
Left:
MEP (daPa)
Tympanometry
Right Left
Masked Air
Bone
Masked Bone
6812 7500 8375
Sound Ear Left
9250
4 kHz
500 Hz
1 kHz
2 kHz
6125
Symbols
Right
No Response
Soundfield
UCL
SDT dB HL
Left
Speech Audiometry
AB word lists
Reliability
Good
Comp. (ml)
Transducer
9 11.2 12.5 14
55002500 2750 40623750
dB HL
Right
3062 3375
Distortion Product Otoacoustic Emissions (DPOAEs)
Left
F2(Hz) 2000 2250
Right
4500 5000
0
10
20
40
30
50
60
70
80
90
100
110
120
0
10
20
40
30
50
60
70
80
90
100
110
120
X
